You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCarbamazepine
Accession NumberDB00564  (APRD00337)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn anticonvulsant used to control grand mal and psychomotor or focal seizures. Its mode of action is not fully understood, but some of its actions resemble those of phenytoin; although there is little chemical resemblance between the two compounds, their three-dimensional structure is similar. [PubChem]
Structure
Thumb
Synonyms
5-Carbamoyl-5H-dibenz(b,f)azepine
5-Carbamoyl-5H-dibenz[b,F]azepine
5-Carbamoyl-5H-dibenzo(b,F)azepine
5-Carbamyl-5H-dibenzo(b,F)azepine
5H-Dibenz(b,F)azepine-5-carboxamide
Carbamazepen
Carbamazepin
Carbamazepina
Carbamazépine
Carbamazepinum
CBZ
External Identifiers
  • G 32 883
  • SPD417
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Bio-carbamazepinetablet200 mgoralBiomed Pharma2003-08-202010-03-16Canada
Carbamazepinecapsule, extended release100 mg/1oralPrasco Laboratories2011-12-15Not applicableUs
Carbamazepinetablet, extended release200 mg/1oralKAISER FOUNDATION HOSPITALS2009-10-28Not applicableUs
Carbamazepinecapsule, extended release200 mg/1oralPrasco Laboratories2011-12-15Not applicableUs
Carbamazepinecapsule, extended release300 mg/1oralPrasco Laboratories2011-12-15Not applicableUs
Carbamazepinecapsule, extended release300 mg/1oralAvera Mc Kennan Hospital2015-06-08Not applicableUs
Carbamazepine 200 Tab 200mgtablet200 mgoralPro Doc Limitee1982-12-312013-07-15Canada
Carbamazepine 200mg Tabletstablet200 mgoralLaboratoires Confab IncNot applicableNot applicableCanada
Carbamazepine CRtablet (extended-release)400 mgoralPro Doc Limitee2013-11-21Not applicableCanada
Carbamazepine CRtablet (extended-release)200 mgoralPro Doc Limitee2013-11-21Not applicableCanada
Carbamazepine ERtablet, extended release200 mg/1oralSandoz Inc1996-03-25Not applicableUs
Carbamazepine ERtablet, extended release200 mg/1oralAmerican Health Packaging2013-06-24Not applicableUs
Carbamazepine ERtablet, extended release400 mg/1oralSandoz Inc1996-03-25Not applicableUs
Carbamazepine ERtablet, extended release400 mg/1oralAmerican Health Packaging2013-06-24Not applicableUs
Carbamazepine ERtablet, extended release400 mg/1oralPhysicians Total Care, Inc.2009-10-16Not applicableUs
Carbamazepine ERtablet, extended release100 mg/1oralSandoz Inc1996-03-25Not applicableUs
Carbamazepine-CR -(200mg)tablet (extended-release)200 mgoralPro Doc Limitee2001-05-222009-07-23Canada
Carbamazepine-CR -(400mg)tablet (extended-release)400 mgoralPro Doc Limitee2001-05-222009-07-23Canada
Carbamazepineer ERtablet, extended release400 mg/1oralREMEDYREPACK INC.2016-01-07Not applicableUs
Carbatrolcapsule, extended release300 mg/1oralPhysicians Total Care, Inc.2009-10-15Not applicableUs
Carbatrolcapsule, extended release100 mg/1oralShire US Manufacturing Inc.1999-12-22Not applicableUs
Carbatrolcapsule, extended release200 mg/1oralShire US Manufacturing Inc.1997-09-30Not applicableUs
Carbatrolcapsule, extended release300 mg/1oralShire US Manufacturing Inc.1997-09-30Not applicableUs
Dom-carbamazepinetablet200 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-carbamazepine CRtablet (extended-release)200 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Dom-carbamazepine CRtablet (extended-release)400 mgoralDominion Pharmacal1998-09-17Not applicableCanada
Equetrocapsule, extended release300 mg/1oralValidus Pharmaceuticals LLC2004-12-10Not applicableUs
Equetrocapsule, extended release100 mg/1oralValidus Pharmaceuticals LLC2004-12-10Not applicableUs
Equetrocapsule, extended release200 mg/1oralValidus Pharmaceuticals LLC2004-12-10Not applicableUs
Mazepinetablet200 mgoralBiomed Pharma1981-12-31Not applicableCanada
Mylan-carbamazepine CRtablet (extended-release)200 mgoralMylan Pharmaceuticals Ulc2000-03-16Not applicableCanada
Mylan-carbamazepine CRtablet (extended-release)400 mgoralMylan Pharmaceuticals Ulc2000-03-16Not applicableCanada
Nu-carbamazepine Tab 200mgtablet200 mgoralNu Pharm Inc1993-12-312012-09-04Canada
PHL-carbamazepine CRtablet (extended-release)200 mgoralPharmel Inc1998-09-032009-10-26Canada
PHL-carbamazepine CRtablet (extended-release)400 mgoralPharmel Inc1998-09-032009-10-26Canada
PMS-carbamazepinetablet (chewable)200 mgoralPharmascience Inc2002-08-13Not applicableCanada
PMS-carbamazepinetablet200 mgoralPharmascience Inc1986-12-31Not applicableCanada
PMS-carbamazepinetablet200 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-carbamazepinetablet (chewable)100 mgoralPharmascience Inc2002-08-13Not applicableCanada
PMS-carbamazepine CRtablet (extended-release)200 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-carbamazepine CRtablet (extended-release)400 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-carbamazepine-CRtablet (extended-release)400 mgoralPharmascience Inc1998-05-28Not applicableCanada
PMS-carbamazepine-CRtablet (extended-release)200 mgoralPharmascience Inc1998-05-28Not applicableCanada
Sandoz-carbamazepine Chewtabstablet200 mgoralSandoz Canada Incorporated2006-02-02Not applicableCanada
Sandoz-carbamazepine Chewtabstablet100 mgoralSandoz Canada Incorporated2006-02-02Not applicableCanada
Sandoz-carbamazepine CRtablet (extended-release)200 mgoralSandoz Canada Incorporated2006-02-02Not applicableCanada
Sandoz-carbamazepine CRtablet (extended-release)400 mgoralSandoz Canada Incorporated2006-02-02Not applicableCanada
Taro-carbamazepinesuspension100 mgoralTaro Pharmaceuticals Inc2011-10-07Not applicableCanada
Taro-carbamazepinetablet200 mgoralTaro Pharmaceuticals Inc2014-05-14Not applicableCanada
Taro-carbamazepine Chewable Tablets 100mgtablet (chewable)100 mgoralTaro Pharmaceuticals Inc2002-04-19Not applicableCanada
Taro-carbamazepine Chewable Tablets 200mgtablet (chewable)200 mgoralTaro Pharmaceuticals Inc2002-04-19Not applicableCanada
Taro-carbamazepine CR 200 mgtablet (extended-release)200 mgoralTaro Pharmaceuticals Inc1998-05-27Not applicableCanada
Taro-carbamazepine CR 400 mgtablet (extended-release)400 mgoralTaro Pharmaceuticals Inc1998-05-27Not applicableCanada
Taro-carbamazepine Tab 200mgtablet200 mgoralTaro Pharmaceuticals Inc1994-12-312001-08-21Canada
Tegretolsuspension100 mg/5mLoralNovartis Pharmaceuticals Corporation1987-12-18Not applicableUs
Tegretoltablet200 mg/1oralNovartis Pharmaceuticals Corporation1968-03-11Not applicableUs
Tegretoltablet200 mg/1oralREMEDYREPACK INC.2015-10-20Not applicableUs
Tegretol - Sus 100mg/5mlsuspension100 mgoralNovartis Pharmaceuticals Canada Inc1996-12-31Not applicableCanada
Tegretol 200mgtablet200 mgoralNovartis Pharmaceuticals Canada Inc1969-12-31Not applicableCanada
Tegretol Chewtabs 100mgtablet100 mgoralNovartis Pharmaceuticals Canada Inc1985-12-31Not applicableCanada
Tegretol Chewtabs 200mgtablet200 mgoralNovartis Pharmaceuticals Canada Inc1985-12-31Not applicableCanada
Tegretol CR Tab 200mgtablet (extended-release)200 mgoralNovartis Pharmaceuticals Canada Inc1988-12-31Not applicableCanada
Tegretol CR Tab 400mgtablet (extended-release)400 mgoralNovartis Pharmaceuticals Canada Inc1988-12-31Not applicableCanada
Tegretol XRtablet, extended release400 mg/1oralNovartis Pharmaceuticals Corporation1996-03-25Not applicableUs
Tegretol XRtablet, extended release100 mg/1oralNovartis Pharmaceuticals Corporation1996-03-25Not applicableUs
Tegretol XRtablet, extended release200 mg/1oralNovartis Pharmaceuticals Corporation1996-03-25Not applicableUs
Tegretolxr XRtablet, extended release100 mg/1oralREMEDYREPACK INC.2015-10-19Not applicableUs
Teva-carbamazepinetablet200 mgoralTeva Canada Limited1988-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Carbamazepine Tab 200mgtablet200 mgoralApotex Inc1980-12-31Not applicableCanada
Apo-carbamazepine CRtablet (extended-release)200 mgoralApotex IncNot applicableNot applicableCanada
Apo-carbamazepine CRtablet (extended-release)400 mgoralApotex IncNot applicableNot applicableCanada
Carbamazepinetablet200 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs1990-09-30Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralCardinal Health2011-10-28Not applicableUs
Carbamazepinetablet200 mg/1oralREMEDYREPACK INC.2014-11-26Not applicableUs
Carbamazepinetablet200 mg/1oralREMEDYREPACK INC.2010-12-02Not applicableUs
Carbamazepinecapsule, extended release200 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2013-06-21Not applicableUs
Carbamazepinetablet, extended release200 mg/1oralAvera Mc Kennan Hospital2015-05-27Not applicableUs
Carbamazepinetablet200 mg/1oralPreferred Pharmaceuticals, Inc.2014-04-02Not applicableUs
Carbamazepinetablet200 mg/1oralA S Medication Solutions Llc1996-10-03Not applicableUs
Carbamazepinetablet200 mg/1oralGolden State Medical Supply, Inc.1996-10-03Not applicableUs
Carbamazepinetablet200 mg/1oralRebel Distributors Corp2009-07-01Not applicableUs
Carbamazepinetablet200 mg/1oralTaro Pharmaceuticals U.S.A., Inc.1996-10-03Not applicableUs
Carbamazepinetablet200 mg/1oralUnit Dose Services1996-10-03Not applicableUs
Carbamazepinetablet100 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Carbamazepinetablet200 mg/1oralMajor Pharmaceuticals2010-09-20Not applicableUs
Carbamazepinesuspension100 mg/5mLoralGolden State Medical Supply, Inc.2004-09-20Not applicableUs
Carbamazepinetablet200 mg/1oralContract Pharmacy Services Pa2010-02-24Not applicableUs
Carbamazepinetablet200 mg/1oralAidarex Pharmaceuticals LLC1996-10-03Not applicableUs
Carbamazepinetablet, extended release200 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2009-03-31Not applicableUs
Carbamazepinecapsule, extended release200 mg/1oralTeva Pharmaceuticals USA Inc2013-02-11Not applicableUs
Carbamazepinetablet, extended release200 mg/1oralCardinal Health2009-03-31Not applicableUs
Carbamazepinecapsule, extended release100 mg/1oralApotex Corp.2012-03-23Not applicableUs
Carbamazepinetablet, extended release400 mg/1oralREMEDYREPACK INC.2016-02-18Not applicableUs
Carbamazepinetablet100 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2005-12-07Not applicableUs
Carbamazepinetablet200 mg/1oralClinical Solutions Wholesale2009-10-23Not applicableUs
Carbamazepinecapsule, extended release200 mg/1oralREMEDYREPACK INC.2015-09-17Not applicableUs
Carbamazepinetablet, chewable200 mg/1oralREMEDYREPACK INC.2013-03-01Not applicableUs
Carbamazepinecapsule, extended release100 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2013-06-21Not applicableUs
Carbamazepinetablet, chewable200 mg/1oralPreferred Pharmaceuticals, Inc2012-04-23Not applicableUs
Carbamazepinetablet200 mg/1oralTeva Pharmaceuticals USA Inc1990-09-30Not applicableUs
Carbamazepinetablet200 mg/1oralPhysicians Total Care, Inc.1993-09-23Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralGolden State Medical Supply, Inc.2000-10-24Not applicableUs
Carbamazepinecapsule, extended release300 mg/1oralNostrum Laboratories, Inc.2011-05-20Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2000-10-24Not applicableUs
Carbamazepinetablet200 mg/1oralMylan Institutional Inc.1995-09-28Not applicableUs
Carbamazepinetablet200 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Carbamazepinetablet200 mg/1oralTorrent Pharmaceuticals Limited2009-10-23Not applicableUs
Carbamazepinecapsule, extended release100 mg/1oralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
Carbamazepinetablet200 mg/1oralAmerican Health Packaging2014-04-15Not applicableUs
Carbamazepinetablet200 mg/1oralPd Rx Pharmaceuticals, Inc.1996-10-03Not applicableUs
Carbamazepinetablet, extended release400 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2009-03-31Not applicableUs
Carbamazepinecapsule, extended release300 mg/1oralTeva Pharmaceuticals USA Inc2013-02-11Not applicableUs
Carbamazepinetablet200 mg/1oralCardinal Health1996-10-03Not applicableUs
Carbamazepinecapsule, extended release200 mg/1oralApotex Corp.2012-03-23Not applicableUs
Carbamazepinetablet200 mg/1oralUpsher Smith Laboratories, Inc1996-10-03Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralClinical Solutions Wholesale2009-08-26Not applicableUs
Carbamazepinetablet200 mg/1oralbryant ranch prepack2011-05-03Not applicableUs
Carbamazepinetablet200 mg/1oralREMEDYREPACK INC.2011-05-16Not applicableUs
Carbamazepinetablet200 mg/1oralREMEDYREPACK INC.2013-05-08Not applicableUs
Carbamazepinetablet200 mg/1oralMc Kesson Contract Packaging2011-10-07Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralTeva Pharmaceuticals USA Inc1995-09-18Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralPhysicians Total Care, Inc.1995-07-27Not applicableUs
Carbamazepinesuspension100 mg/5mLoralMorton Grove Pharmaceuticals, Inc.2002-06-05Not applicableUs
Carbamazepinecapsule, extended release100 mg/1oralNostrum Laboratories, Inc.2011-05-20Not applicableUs
Carbamazepinesuspension100 mg/5mLoralTaro Pharmaceuticals U.S.A., Inc.2004-09-20Not applicableUs
Carbamazepinesuspension200 mg/10mLoralPrecision Dose Inc.2003-09-02Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralMylan Institutional Inc.1996-05-15Not applicableUs
Carbamazepinetablet200 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralTorrent Pharmaceuticals Limited2009-08-26Not applicableUs
Carbamazepinecapsule, extended release200 mg/1oralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralCardinal Health2000-10-24Not applicableUs
Carbamazepinecapsule, extended release300 mg/1oralApotex Corp.2012-03-23Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralREMEDYREPACK INC.2011-08-17Not applicableUs
Carbamazepinecapsule, extended release300 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2013-06-21Not applicableUs
Carbamazepinetablet200 mg/1oralActavis Elizabeth LLC1995-01-03Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralState of Florida DOH Central Pharmacy2013-01-01Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralMajor Pharmaceuticals2010-03-22Not applicableUs
Carbamazepinetablet200 mg/1oralGolden State Medical Supply, Inc.2014-03-07Not applicableUs
Carbamazepinetablet200 mg/1oralTYA Pharmaceuticals1996-10-03Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralREMEDYREPACK INC.2011-07-13Not applicableUs
Carbamazepinecapsule, extended release200 mg/1oralNostrum Laboratories, Inc.2011-05-20Not applicableUs
Carbamazepinetablet, extended release100 mg/1oralTaro Pharmaceuticals U.S.A., Inc.2009-03-31Not applicableUs
Carbamazepinetablet, chewable100 mg/1oralMc Kesson Contract Packaging2011-09-01Not applicableUs
Carbamazepinecapsule, extended release100 mg/1oralTeva Pharmaceuticals USA Inc2013-07-15Not applicableUs
Carbamazepinetablet200 mg/1oralCardinal Health2010-09-20Not applicableUs
Carbamazepinetablet200 mg/1oralApotex Corp.2002-09-01Not applicableUs
Carbamazepinetablet200 mg/1oralSTAT Rx USA LLC2009-12-08Not applicableUs
Carbamazepinecapsule, extended release300 mg/1oralGolden State Medical Supply, Inc.2011-05-20Not applicableUs
Carbamazepinesuspension100 mg/5mLoralPrecision Dose Inc.2007-02-27Not applicableUs
Carbamazepinetablet200 mg/1oralNorthwind Pharmaceuticals, LLC2015-03-03Not applicableUs
Carbamazepinetablet, extended release400 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Epitoltablet200 mg/1oralTeva Pharmaceuticals USA Inc1990-09-30Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ActebralSanofi-Aventis
AnlepticSquare
BistonZentiva
CarbamatAstraZeneca
NeurotopGerot
TEGretol ChewtabsNot Available
TEGretol-CRNovartis
TEGretol-XRNovartis
TerilTaro
TimonilDesitin
VersitolMicro Synapse
VersizurMicro Labs
Brand mixturesNot Available
SaltsNot Available
Categories
UNII33CM23913M
CAS number298-46-4
WeightAverage: 236.2686
Monoisotopic: 236.094963016
Chemical FormulaC15H12N2O
InChI KeyInChIKey=FFGPTBGBLSHEPO-UHFFFAOYSA-N
InChI
InChI=1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
IUPAC Name
2-azatricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaene-2-carboxamide
SMILES
NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as dibenzazepines. These are compounds with two benzene rings connected by an azepine ring. Azepine is an unsaturated seven-member heterocycle with one nitrogen atom replacing a carbon atom.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzazepines
Sub ClassDibenzazepines
Direct ParentDibenzazepines
Alternative Parents
Substituents
  • Dibenzazepine
  • Azepine
  • Benzenoid
  • Urea
  • Tertiary amine
  • Azacycle
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of epilepsy and pain associated with true trigeminal neuralgia.
PharmacodynamicsCarbamazepine, an anticonvulsant structurally similar to tricyclic antidepressants, is used to treat partial seizures, tonic-clonic seizures, pain of neurologic origin such as trigeminal neuralgia, and psychiatric disorders including manic-depressive illness and aggression due to dementia. The response to carbamazepine is variable and may be due to its variable transport, especially across the blood-brain-barrier. The transporter that may confer drug resistance is RALBP1.
Mechanism of actionCarbamazepine inhibits sustained repetitive firing by blocking use-dependent sodium channels. Pain relief is believed to be associated with blockade of synaptic transmission in the trigeminal nucleus and seizure control with reduction of post-tetanic potentiation of synaptic transmission in the spinal cord. Carbamazepine also possesses anticholinergic, central antidiuretic, antiarrhythmic, muscle relaxant, antidepressant (possibly through blockade of norepinephrine release), sedative, and neuromuscular-blocking properties.
Related Articles
AbsorptionIn clinical studies, carbamazepine suspension, conventional tablets, and extended-release tablets delivered equivalent amounts of drug to the systemic circulation. However, it has been observed that the suspension is somewhat faster absorbed. Furthermore, the extended-release tablet is slightly slower than the conventional tablet. The bioavailability of the extended-release tablet is 89%, compared to the suspension. Plasma levels of carbamazepine are variable. The time to peak concentration for the different formulations are as follows: Suspension = 1.5 hours; Conventional tablets = 4-5 hours; Extended-release tablets = 3-12 hours.
Volume of distributionNot Available
Protein binding76% bound to plasma proteins.
Metabolism

Hepatic. CYP3A4 is the primary isoform responsible for the formation of carbamazepine-10,11-epoxide. This metabolite is active and shown to be equipotent to carbamazepine as an anticonvulsant. Carbamazepine is more rapidly metabolized to the aforementioned metabolite in younger patients than in adults. It also undergoes glucuronidation via UGT2B7, however this finding has been disputed.

SubstrateEnzymesProduct
Carbamazepine
10,11-EpoxycarbamazepineDetails
Carbamazepine
3-hydroxycarbamazepineDetails
Carbamazepine
Not Available
Carbamazepine 2,3-epoxideDetails
3-hydroxycarbamazepine
2,3-DihydroxycarbamazepineDetails
Carbamazepine 2,3-epoxide
Not Available
2-hydroxycarbamazepineDetails
2-hydroxycarbamazepine
2-hydroxyiminostilbeneDetails
2-hydroxyiminostilbene
Not Available
Carbamazepine iminoquinoneDetails
2-hydroxycarbamazepine
Not Available
2,3-DihydroxycarbamazepineDetails
2,3-Dihydroxycarbamazepine
Not Available
Carbamazepine-O-quinoneDetails
10,11-Epoxycarbamazepine
10,11-DihydroxycarbamazepineDetails
Carbamazepine 2,3-epoxide
Not Available
3-hydroxycarbamazepineDetails
Route of elimination72% of the dose is in the urine while 28% is in the feces. Hydroxylated and conjugated metabolites are largely what was recovered in the urine. 3% of the dose is recovered as unchanged carbamazepine.
Half lifeInitial half-life values range from 25-65 hours, decreasing to 12-17 hours on repeated doses.
ClearanceNot Available
ToxicityMild ingestions cause vomiting, drowsiness, ataxia, slurred speech, nystagmus, dystonic reactions, and hallucinations. Severe intoxications may produce coma, seizures, respiratory depression, and hypotension
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Carbamazepine Metabolism PathwayDrug metabolismSMP00634
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Sodium channel protein type 1 subunit alpha
Gene symbol: SCN1A
UniProt: P35498
rs3812718 Not AvailableIVS5N + 5 G>ACarbamazepine resistant therapy, higher maintenance dose24052718
SNP Mediated Adverse Drug Reactions
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeAdverse ReactionReference(s)
Heat shock 70 kDa protein 1-like
Gene symbol: HSPA1L
UniProt: P34931
rs2227956 Not AvailableT alleleHypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538175
Heat shock 70 kDa protein 1A/1B
Gene symbol: HSPA1A
UniProt: P08107
rs506770 Not AvailableC alleleHypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538175
Heat shock 70 kDa protein 1A/1B
Gene symbol: HSPA1A
UniProt: P08107
rs1043620 Not AvailableC alleleHypersensitivity reaction, mild erythematous skin rashes, macropapular eruption, Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538175
HLA class I histocompatibility antigen, B-15 alpha chain
Gene symbol: HLA-B
UniProt: P30464
rs3130690 Not AvailableT alleleStevens-Johnson syndrome (SJS), toxic epidermal necrolysis16538176
HLA class I histocompatibility antigen, A-31 alpha chain
Gene symbol: HLA-A
UniProt: P16189
rs1264511 Not AvailableG alleleMacropapular eruption16538176
Promotilin
Gene symbol: MLN
UniProt: P12872
rs2894342 Not AvailableA alleleHypersensitivity syndrome16538176
Flotillin-1
Gene symbol: FLOT1
UniProt: O75955
rs3909184 HLA-B*1502G > CPatients with the CG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the CC genotype (non-carriers of HLA-b*1502)18637831
Mucin-21
Gene symbol: MUC21
UniProt: Q5SSG8
rs2844682 HLA-B*1502G>APatients with the AG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the AA genotype18637831
Flotillin-1
Gene symbol: FLOT1
UniProt: O75955
rs3909184 HLA-B*1502G > CPatients with the CG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the CC genotype (non-carriers of HLA-b*1502)15057820
Mucin-21
Gene symbol: MUC21
UniProt: Q5SSG8
rs2844682 HLA-B*1502G>APatients with the AG or GG genotype (in Asian patients) were at a higher risk of Steven-Johnson Syndrome compared to those with the AA genotype15057820
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9962
Blood Brain Barrier+0.9958
Caco-2 permeable+0.6538
P-glycoprotein substrateNon-substrate0.6466
P-glycoprotein inhibitor INon-inhibitor0.8748
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.8177
CYP450 2C9 substrateNon-substrate0.7466
CYP450 2D6 substrateSubstrate0.884
CYP450 3A4 substrateNon-substrate0.6204
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8222
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7358
Ames testNon AMES toxic0.5554
CarcinogenicityNon-carcinogens0.8848
BiodegradationNot ready biodegradable0.978
Rat acute toxicity2.1131 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9653
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Shire development inc
  • Validus pharmaceuticals inc
  • Taro pharmaceutical industries ltd
  • Wockhardt eu operations (swiss) ag
  • Novartis pharmaceuticals corp
  • Taro pharmaceuticals usa inc
  • Cadista pharmaceuticals inc
  • Torrent pharmaceuticals ltd
  • Teva pharmaceuticals usa inc
  • Actavis elizabeth llc
  • Apotex inc etobicoke site
  • Inwood laboratories inc sub forest laboratories inc
  • Pliva inc
  • Usl pharma inc
  • Warner chilcott div warner lambert co
Packagers
Dosage forms
FormRouteStrength
Tabletoral200 mg
Capsule, extended releaseoral100 mg/1
Capsule, extended releaseoral200 mg/1
Capsule, extended releaseoral300 mg/1
Suspensionoral200 mg/10mL
Tabletoral100 mg/1
Tablet, chewableoral100 mg/1
Tablet, chewableoral200 mg/1
Tablet (chewable)oral100 mg
Tablet (chewable)oral200 mg
Tablet (extended-release)oral200 mg
Tablet (extended-release)oral400 mg
Suspensionoral100 mg/5mL
Tabletoral200 mg/1
Suspensionoral100 mg
Tabletoral100 mg
Tablet, extended releaseoral100 mg/1
Tablet, extended releaseoral200 mg/1
Tablet, extended releaseoral400 mg/1
Prices
Unit descriptionCostUnit
Equetro 300 mg capsule2.65USD capsule
TEGretol XR 400 mg 12 Hour tablet2.42USD tablet
Carbamazepine powder2.26USD g
Tegretol xr 400 mg tablet2.19USD tablet
Carbatrol 100 mg 12 Hour Capsule2.18USD capsule
Equetro 200 mg capsule2.15USD capsule
CarBAMazepine 400 mg 12 Hour tablet2.05USD tablet
Carbatrol 300 mg 12 Hour Capsule1.95USD capsule
Carbatrol 200 mg 12 Hour Capsule1.92USD capsule
Carbatrol er 100 mg capsule1.84USD capsule
Carbatrol er 200 mg capsule1.84USD capsule
Carbatrol er 300 mg capsule1.84USD capsule
Equetro 100 mg capsule1.74USD capsule
TEGretol XR 200 mg 12 Hour tablet1.45USD tablet
Tegretol xr 200 mg tablet1.1USD tablet
CarBAMazepine 200 mg 12 Hour tablet1.03USD tablet
TEGretol XR 100 mg 12 Hour tablet0.97USD tablet
Tegretol Cr 400 mg Sustained-Release Tablet0.84USD tablet
Tegretol 200 mg tablet0.75USD tablet
Tegretol xr 100 mg tablet0.55USD tablet
Tegretol Cr 200 mg Sustained-Release Tablet0.42USD tablet
Mylan-Carbamazepine Cr 400 mg Sustained-Release Tablet0.4USD tablet
Pms-Carbamazepine-Cr 400 mg Sustained-Release Tablet0.4USD tablet
Sandoz Carbamazepine Cr 400 mg Sustained-Release Tablet0.4USD tablet
Tegretol 200 mg Chewable Tablet0.34USD tablet
Carbamazepine 200 mg tablet0.31USD tablet
Epitol 200 mg tablet0.3USD tablet
CarBAMazepine 100 mg Chew Tabs0.25USD tab
Mylan-Carbamazepine Cr 200 mg Sustained-Release Tablet0.2USD tablet
Pms-Carbamazepine-Cr 200 mg Sustained-Release Tablet0.2USD tablet
Sandoz Carbamazepine Cr 200 mg Sustained-Release Tablet0.2USD tablet
Tegretol 100 mg Chewable Tablet0.17USD tablet
CarBAMazepine 100 mg/5ml Suspension0.16USD ml
Pms-Carbamazepine 200 mg Chewable Tablet0.16USD tablet
Sandoz Carbamazepine 200 mg Chewable Tablet0.16USD tablet
Taro-Carbamazepine 200 mg Chewable Tablet0.16USD tablet
Apo-Carbamazepine 200 mg Tablet0.08USD tablet
Novo-Carbamaz 200 mg Tablet0.08USD tablet
Nu-Carbamazepine 200 mg Tablet0.08USD tablet
Pms-Carbamazepine 100 mg Chewable Tablet0.08USD tablet
Sandoz Carbamazepine 100 mg Chewable Tablet0.08USD tablet
Taro-Carbamazepine 100 mg Chewable Tablet0.08USD tablet
Tegretol 20 mg/ml Suspension0.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5284662 No1994-02-082011-02-08Us
US5912013 No1996-06-152016-06-15Us
US6977253 No2004-05-192024-05-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point204-206Schindier, W.; U.S. Patent 2,948,718; August 9, 1960; assigned to Geigy Chemical Corporation.
water solubility17.7 mg/LNot Available
logP2.45DAL POZZO,A ET AL. (1989)
Predicted Properties
PropertyValueSource
Water Solubility0.152 mg/mLALOGPS
logP2.1ALOGPS
logP2.77ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)15.96ChemAxon
pKa (Strongest Basic)-3.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.33 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity71.89 m3·mol-1ChemAxon
Polarizability25 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (7.72 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0006-1910000000-4b2dc85e8da73b101ed2View in MoNA
1D NMR1H NMR SpectrumNot Available
References
Synthesis Reference

Ketan Dhansukhlal Vyas, Wajid Sajjad Jafri, Ashok Krishna Kulkarni, “Process for preparing carbamazepine from iminostilbene.” U.S. Patent US6245908, issued February, 1998.

US6245908
General References
  1. Staines AG, Coughtrie MW, Burchell B: N-glucuronidation of carbamazepine in human tissues is mediated by UGT2B7. J Pharmacol Exp Ther. 2004 Dec;311(3):1131-7. Epub 2004 Aug 3. [PubMed:15292462 ]
  2. Sisodiya SM, Goldstein DB: Drug resistance in epilepsy: more twists in the tale. Epilepsia. 2007 Dec;48(12):2369-70. [PubMed:18088268 ]
External Links
ATC CodesN03AF01
AHFS Codes
  • 28:12.92
PDB EntriesNot Available
FDA labelDownload (55.9 KB)
MSDSDownload (71.6 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe metabolism of 1,10-Phenanthroline can be increased when combined with Carbamazepine.
3,4-DichloroisocoumarinThe metabolism of 3,4-Dichloroisocoumarin can be increased when combined with Carbamazepine.
4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDEThe metabolism of 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE can be increased when combined with Carbamazepine.
4-AndrostenedioneThe serum concentration of 4-Androstenedione can be decreased when it is combined with Carbamazepine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when Carbamazepine is combined with 7-Nitroindazole.
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINEThe risk or severity of adverse effects can be increased when Carbamazepine is combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.
AbirateroneThe serum concentration of Carbamazepine can be increased when it is combined with Abiraterone.
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Carbamazepine.
AcebutololThe serum concentration of Acebutolol can be decreased when it is combined with Carbamazepine.
AceclofenacThe metabolism of Aceclofenac can be increased when combined with Carbamazepine.
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Carbamazepine.
AcepromazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Acepromazine.
AceprometazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Aceprometazine.
AcetaminophenThe metabolism of Acetaminophen can be increased when combined with Carbamazepine.
AcetaminophenThe serum concentration of Carbamazepine can be increased when it is combined with Acetaminophen.
AcetazolamideThe serum concentration of Carbamazepine can be increased when it is combined with Acetazolamide.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be decreased when it is combined with Carbamazepine.
AdenosineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Adenosine.
AdinazolamThe metabolism of Adinazolam can be increased when combined with Carbamazepine.
adipiplonThe risk or severity of adverse effects can be increased when Carbamazepine is combined with adipiplon.
AfatinibThe serum concentration of Afatinib can be decreased when it is combined with Carbamazepine.
AfatinibThe serum concentration of Carbamazepine can be increased when it is combined with Afatinib.
AgomelatineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Agomelatine.
AlbendazoleThe serum concentration of the active metabolites of Albendazole can be reduced when Albendazole is used in combination with Carbamazepine resulting in a loss in efficacy.
AlbendazoleThe serum concentration of Carbamazepine can be increased when it is combined with Albendazole.
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Carbamazepine.
AldosteroneThe serum concentration of Aldosterone can be decreased when it is combined with Carbamazepine.
AlectinibThe serum concentration of Carbamazepine can be increased when it is combined with Alectinib.
AlfaxaloneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Alfaxalone.
AlfentanilThe serum concentration of Carbamazepine can be increased when it is combined with Alfentanil.
AlfentanilThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Alfentanil.
AlfuzosinThe metabolism of Alfuzosin can be increased when combined with Carbamazepine.
AliskirenThe metabolism of Aliskiren can be increased when combined with Carbamazepine.
AlitretinoinThe serum concentration of Alitretinoin can be decreased when it is combined with Carbamazepine.
AllopurinolThe serum concentration of Carbamazepine can be increased when it is combined with Allopurinol.
AllylestrenolThe metabolism of Allylestrenol can be increased when combined with Carbamazepine.
AlmotriptanThe metabolism of Almotriptan can be increased when combined with Carbamazepine.
AlogliptinThe metabolism of Alogliptin can be increased when combined with Carbamazepine.
AlosetronThe metabolism of Alosetron can be increased when combined with Carbamazepine.
Alpha-1-proteinase inhibitorThe metabolism of Alpha-1-proteinase inhibitor can be increased when combined with Carbamazepine.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Alphacetylmethadol.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Carbamazepine.
AmantadineThe serum concentration of Carbamazepine can be increased when it is combined with Amantadine.
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Carbamazepine.
AmbroxolThe metabolism of Ambroxol can be increased when combined with Carbamazepine.
AmcinonideThe serum concentration of Amcinonide can be decreased when it is combined with Carbamazepine.
AmineptineThe metabolism of Amineptine can be increased when combined with Carbamazepine.
Aminohippuric acidThe serum concentration of Carbamazepine can be increased when it is combined with Aminohippuric acid.
AminophenazoneThe metabolism of Aminophenazone can be increased when combined with Carbamazepine.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Carbamazepine.
AmiodaroneThe metabolism of Amiodarone can be increased when combined with Carbamazepine.
AmiodaroneThe serum concentration of Carbamazepine can be decreased when it is combined with Amiodarone.
AmisulprideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amisulpride.
AmitriptylineThe metabolism of Amitriptyline can be increased when combined with Carbamazepine.
AmitriptylineThe serum concentration of Carbamazepine can be increased when it is combined with Amitriptyline.
AmlodipineThe metabolism of Amlodipine can be increased when combined with Carbamazepine.
AmlodipineThe serum concentration of Carbamazepine can be increased when it is combined with Amlodipine.
AmobarbitalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amobarbital.
AmodiaquineThe metabolism of Amodiaquine can be increased when combined with Carbamazepine.
AmoxapineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amoxapine.
AmoxicillinThe metabolism of Amoxicillin can be increased when combined with Carbamazepine.
AmperozideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Amperozide.
AmprenavirThe metabolism of Amprenavir can be increased when combined with Carbamazepine.
AmprenavirThe serum concentration of Carbamazepine can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Carbamazepine can be increased when it is combined with Amsacrine.
AnagrelideThe metabolism of Anagrelide can be increased when combined with Carbamazepine.
AntipyrineThe metabolism of Antipyrine can be increased when combined with Carbamazepine.
Antithrombin III humanThe metabolism of Antithrombin III human can be increased when combined with Carbamazepine.
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Carbamazepine.
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Carbamazepine.
AprepitantThe serum concentration of Carbamazepine can be increased when it is combined with Aprepitant.
AprepitantThe metabolism of Aprepitant can be increased when combined with Carbamazepine.
AprotininThe metabolism of Aprotinin can be increased when combined with Carbamazepine.
Arachidonic AcidThe metabolism of Arachidonic Acid can be increased when combined with Carbamazepine.
ArformoterolThe metabolism of Arformoterol can be increased when combined with Carbamazepine.
ArgatrobanThe metabolism of Argatroban can be increased when combined with Carbamazepine.
AripiprazoleThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Aripiprazole.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be decreased when it is combined with Carbamazepine.
ArtemetherThe serum concentration of the active metabolites of Artemether can be reduced when Artemether is used in combination with Carbamazepine resulting in a loss in efficacy.
ArticaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Articaine.
ASA404The metabolism of ASA404 can be increased when combined with Carbamazepine.
AsenapineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Asenapine.
AstemizoleThe metabolism of Astemizole can be increased when combined with Carbamazepine.
AstemizoleThe serum concentration of Carbamazepine can be increased when it is combined with Astemizole.
AsunaprevirThe metabolism of Asunaprevir can be increased when combined with Carbamazepine.
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Carbamazepine.
AtazanavirThe serum concentration of Carbamazepine can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be decreased when it is combined with Carbamazepine.
AtenololThe serum concentration of Carbamazepine can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Carbamazepine can be decreased when combined with Atomoxetine.
AtorvastatinThe metabolism of Atorvastatin can be increased when combined with Carbamazepine.
AtorvastatinThe serum concentration of Carbamazepine can be increased when it is combined with Atorvastatin.
AV650The metabolism of AV650 can be increased when combined with Carbamazepine.
AvanafilThe metabolism of Avanafil can be increased when combined with Carbamazepine.
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Carbamazepine.
AzaperoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Azaperone.
AzelastineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe serum concentration of Carbamazepine can be increased when it is combined with Azelastine.
AzithromycinThe metabolism of Azithromycin can be increased when combined with Carbamazepine.
AzithromycinThe serum concentration of Carbamazepine can be increased when it is combined with Azithromycin.
BaclofenThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Baclofen.
BanoxantroneThe metabolism of Banoxantrone can be increased when combined with Carbamazepine.
BarbitalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Barbital.
BatimastatThe metabolism of Batimastat can be increased when combined with Carbamazepine.
BazedoxifeneThe serum concentration of Bazedoxifene can be decreased when it is combined with Carbamazepine.
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be decreased when it is combined with Carbamazepine.
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Carbamazepine.
BenazeprilThe metabolism of Benazepril can be increased when combined with Carbamazepine.
BendamustineThe serum concentration of Bendamustine can be decreased when it is combined with Carbamazepine.
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Carbamazepine.
BenmoxinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Benmoxin.
BenzamidineThe metabolism of Benzamidine can be increased when combined with Carbamazepine.
BenzatropineThe metabolism of Benzatropine can be increased when combined with Carbamazepine.
BenzocaineThe serum concentration of Carbamazepine can be increased when it is combined with Benzocaine.
BenzocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Benzocaine.
BenzphetamineThe metabolism of Benzphetamine can be increased when combined with Carbamazepine.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Benzyl alcohol.
BepridilThe serum concentration of Carbamazepine can be increased when it is combined with Bepridil.
BeraprostThe metabolism of Beraprost can be increased when combined with Carbamazepine.
BetamethasoneThe serum concentration of Betamethasone can be decreased when it is combined with Carbamazepine.
BetaxololThe metabolism of Betaxolol can be increased when combined with Carbamazepine.
BexaroteneThe serum concentration of Carbamazepine can be decreased when it is combined with Bexarotene.
BexaroteneThe metabolism of Bexarotene can be increased when combined with Carbamazepine.
BezafibrateThe metabolism of Bezafibrate can be increased when combined with Carbamazepine.
BicalutamideThe metabolism of Bicalutamide can be increased when combined with Carbamazepine.
BiperidenThe serum concentration of Carbamazepine can be increased when it is combined with Biperiden.
BisoprololThe metabolism of Bisoprolol can be increased when combined with Carbamazepine.
BivalirudinThe metabolism of Bivalirudin can be increased when combined with Carbamazepine.
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Carbamazepine.
BoceprevirThe metabolism of Carbamazepine can be decreased when combined with Boceprevir.
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Carbamazepine.
BortezomibThe metabolism of Carbamazepine can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Carbamazepine can be decreased when it is combined with Bosentan.
BosentanThe metabolism of Bosentan can be increased when combined with Carbamazepine.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Carbamazepine.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Carbamazepine.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
BrimonidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Brimonidine.
BrinzolamideThe serum concentration of Carbamazepine can be increased when it is combined with Brinzolamide.
BrinzolamideThe metabolism of Brinzolamide can be increased when combined with Carbamazepine.
BromazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Bromazepam.
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Carbamazepine.
BromocriptineThe serum concentration of Carbamazepine can be increased when it is combined with Bromocriptine.
BrompheniramineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Brompheniramine.
BrotizolamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Brotizolam.
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Carbamazepine.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Carbamazepine.
BuprenorphineThe serum concentration of Carbamazepine can be increased when it is combined with Buprenorphine.
BuprenorphineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Buprenorphine.
BupropionThe metabolism of Bupropion can be increased when combined with Carbamazepine.
BuspironeThe serum concentration of Carbamazepine can be increased when it is combined with Buspirone.
BuspironeThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Buspirone.
BusulfanThe metabolism of Busulfan can be increased when combined with Carbamazepine.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Carbamazepine.
ButacaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butacaine.
ButalbitalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butalbital.
ButambenThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butamben.
ButethalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butethal.
ButorphanolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Butorphanol.
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Carbamazepine.
CabazitaxelThe serum concentration of Carbamazepine can be increased when it is combined with Cabazitaxel.
CabergolineThe metabolism of Cabergoline can be increased when combined with Carbamazepine.
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Carbamazepine.
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Carbamazepine.
CaffeineThe serum concentration of Carbamazepine can be increased when it is combined with Caffeine.
CalcitriolThe metabolism of Calcitriol can be increased when combined with Carbamazepine.
CamptothecinThe serum concentration of Camptothecin can be decreased when it is combined with Carbamazepine.
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Carbamazepine.
CanagliflozinThe serum concentration of Carbamazepine can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Carbamazepine can be increased when it is combined with Candesartan.
CandesartanThe metabolism of Candesartan can be increased when combined with Carbamazepine.
CandoxatrilThe metabolism of Candoxatril can be increased when combined with Carbamazepine.
CannabidiolThe serum concentration of Cannabidiol can be decreased when it is combined with Carbamazepine.
CaptoprilThe metabolism of Captopril can be increased when combined with Carbamazepine.
CaptoprilThe serum concentration of Carbamazepine can be increased when it is combined with Captopril.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Carbinoxamine.
CarfentanilThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Carfentanil.
CarfilzomibThe serum concentration of Carfilzomib can be decreased when it is combined with Carbamazepine.
CariprazineThe metabolism of Cariprazine can be increased when combined with Carbamazepine.
CarisoprodolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Carisoprodol.
CarmustineThe metabolism of Carmustine can be increased when combined with Carbamazepine.
CaroxazoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Caroxazone.
CarvedilolThe metabolism of Carvedilol can be increased when combined with Carbamazepine.
CarvedilolThe serum concentration of Carbamazepine can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Carbamazepine.
CaspofunginThe serum concentration of Carbamazepine can be increased when it is combined with Caspofungin.
CelecoxibThe metabolism of Celecoxib can be increased when combined with Carbamazepine.
CeliprololThe metabolism of Celiprolol can be increased when combined with Carbamazepine.
CephalexinThe metabolism of Cephalexin can be increased when combined with Carbamazepine.
CeritinibThe serum concentration of Carbamazepine can be increased when it is combined with Ceritinib.
CeritinibThe serum concentration of Ceritinib can be decreased when it is combined with Carbamazepine.
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Carbamazepine.
CetirizineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cetirizine.
CevimelineThe metabolism of Cevimeline can be increased when combined with Carbamazepine.
Chenodeoxycholic acidThe metabolism of Chenodeoxycholic acid can be increased when combined with Carbamazepine.
Chloral hydrateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chloral hydrate.
ChloramphenicolThe metabolism of Chloramphenicol can be increased when combined with Carbamazepine.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Carbamazepine.
ChlormezanoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chlormezanone.
ChloroprocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chloroprocaine.
ChloroquineThe metabolism of Chloroquine can be increased when combined with Carbamazepine.
ChloroquineThe serum concentration of Carbamazepine can be increased when it is combined with Chloroquine.
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Carbamazepine.
ChlorphenamineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chlorphenamine.
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Carbamazepine.
ChlorpromazineThe serum concentration of Carbamazepine can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe serum concentration of Carbamazepine can be increased when it is combined with Chlorpropamide.
ChlorpropamideThe metabolism of Chlorpropamide can be increased when combined with Carbamazepine.
ChlorprothixeneThe serum concentration of Carbamazepine can be increased when it is combined with Chlorprothixene.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chlorprothixene.
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Carbamazepine.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chlorzoxazone.
CholecalciferolThe metabolism of Cholecalciferol can be increased when combined with Carbamazepine.
CholesterolThe serum concentration of Carbamazepine can be increased when it is combined with Cholesterol.
Cholic AcidThe serum concentration of Carbamazepine can be decreased when it is combined with Cholic Acid.
ChymostatinThe metabolism of Chymostatin can be increased when combined with Carbamazepine.
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Carbamazepine.
CilastatinThe metabolism of Cilastatin can be increased when combined with Carbamazepine.
CilazaprilThe metabolism of Cilazapril can be increased when combined with Carbamazepine.
CilazaprilThe serum concentration of Carbamazepine can be increased when it is combined with Cilazapril.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Carbamazepine.
CimetidineThe serum concentration of Carbamazepine can be increased when it is combined with Cimetidine.
CimetidineThe serum concentration of Cimetidine can be decreased when it is combined with Carbamazepine.
CinacalcetThe metabolism of Cinacalcet can be increased when combined with Carbamazepine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Carbamazepine.
CinnarizineThe metabolism of Cinnarizine can be increased when combined with Carbamazepine.
CiprofloxacinThe serum concentration of Carbamazepine can be increased when it is combined with Ciprofloxacin.
CiprofloxacinThe serum concentration of Ciprofloxacin can be decreased when it is combined with Carbamazepine.
CisaprideThe metabolism of Cisapride can be increased when combined with Carbamazepine.
CisplatinThe serum concentration of Cisplatin can be decreased when it is combined with Carbamazepine.
CitalopramThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Citalopram.
CitalopramThe serum concentration of Carbamazepine can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Carbamazepine.
ClarithromycinThe serum concentration of Carbamazepine can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Carbamazepine can be decreased when combined with Clemastine.
ClemastineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Clemastine.
ClenbuterolThe metabolism of Clenbuterol can be increased when combined with Carbamazepine.
ClevidipineThe metabolism of Clevidipine can be increased when combined with Carbamazepine.
ClidiniumThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Clidinium.
ClindamycinThe metabolism of Clindamycin can be increased when combined with Carbamazepine.
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Carbamazepine.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Carbamazepine.
Clobetasol propionateThe serum concentration of Clobetasol propionate can be decreased when it is combined with Carbamazepine.
ClocortoloneThe serum concentration of Clocortolone can be decreased when it is combined with Carbamazepine.
ClofazimineThe metabolism of Clofazimine can be increased when combined with Carbamazepine.
ClofazimineThe serum concentration of Carbamazepine can be increased when it is combined with Clofazimine.
ClofibrateThe metabolism of Clofibrate can be increased when combined with Carbamazepine.
clomethiazoleThe risk or severity of adverse effects can be increased when Carbamazepine is combined with clomethiazole.
ClomifeneThe serum concentration of Clomifene can be decreased when it is combined with Carbamazepine.
ClomipramineThe metabolism of Clomipramine can be increased when combined with Carbamazepine.
ClomipramineThe serum concentration of Carbamazepine can be increased when it is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Clonazepam.
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Carbamazepine.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Carbamazepine.
ClopidogrelThe serum concentration of Clopidogrel can be decreased when it is combined with Carbamazepine.
ClopidogrelThe metabolism of Carbamazepine can be decreased when combined with Clopidogrel.
ClorazepateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Clorazepate.
ClotiazepamThe metabolism of Clotiazepam can be increased when combined with Carbamazepine.
ClotrimazoleThe metabolism of Carbamazepine can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Clozapine.
CobicistatThe serum concentration of Cobicistat can be decreased when it is combined with Carbamazepine.
CobicistatThe serum concentration of Carbamazepine can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Carbamazepine.
CocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cocaine.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Carbamazepine.
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Carbamazepine.
ColchicineThe serum concentration of Carbamazepine can be increased when it is combined with Colchicine.
ColforsinThe serum concentration of Carbamazepine can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Carbamazepine can be increased when it is combined with Conivaptan.
ConivaptanThe metabolism of Conivaptan can be increased when combined with Carbamazepine.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Carbamazepine.
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Carbamazepine.
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Carbamazepine.
CrizotinibThe metabolism of Carbamazepine can be decreased when combined with Crizotinib.
CyclizineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cyclizine.
CyclobenzaprineThe metabolism of Cyclobenzaprine can be increased when combined with Carbamazepine.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carbamazepine.
CyclophosphamideThe metabolism of Cyclophosphamide can be increased when combined with Carbamazepine.
CyclophosphamideThe serum concentration of Carbamazepine can be increased when it is combined with Cyclophosphamide.
CyclosporineThe metabolism of Carbamazepine can be decreased when combined with Cyclosporine.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Carbamazepine.
CyproheptadineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Cyproheptadine.
Cyproterone acetateThe serum concentration of Carbamazepine can be decreased when it is combined with Cyproterone acetate.
CytarabineThe metabolism of Cytarabine can be increased when combined with Carbamazepine.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be decreased when it is combined with Carbamazepine.
DabrafenibThe serum concentration of Carbamazepine can be decreased when it is combined with Dabrafenib.
DacarbazineThe metabolism of Dacarbazine can be increased when combined with Carbamazepine.
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Carbamazepine.
DaclatasvirThe serum concentration of Carbamazepine can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Dactinomycin can be decreased when it is combined with Carbamazepine.
DactinomycinThe serum concentration of Carbamazepine can be increased when it is combined with Dactinomycin.
DanazolThe metabolism of Carbamazepine can be decreased when combined with Danazol.
DantroleneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dantrolene.
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Carbamazepine.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Carbamazepine.
DapoxetineThe metabolism of Carbamazepine can be decreased when combined with Dapoxetine.
DapoxetineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dapoxetine.
DapsoneThe metabolism of Dapsone can be increased when combined with Carbamazepine.
DarifenacinThe metabolism of Darifenacin can be increased when combined with Carbamazepine.
DarunavirThe metabolism of Darunavir can be increased when combined with Carbamazepine.
DarunavirThe serum concentration of Carbamazepine can be increased when it is combined with Darunavir.
DasabuvirThe metabolism of Dasabuvir can be increased when combined with Carbamazepine.
DasatinibThe serum concentration of Carbamazepine can be increased when it is combined with Dasatinib.
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Carbamazepine.
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Carbamazepine.
DebrisoquinThe serum concentration of Debrisoquin can be decreased when it is combined with Carbamazepine.
DeferasiroxThe serum concentration of Carbamazepine can be decreased when it is combined with Deferasirox.
DehydroepiandrosteroneThe serum concentration of Dehydroepiandrosterone can be decreased when it is combined with Carbamazepine.
dehydroepiandrosterone sulfateThe serum concentration of dehydroepiandrosterone sulfate can be decreased when it is combined with Carbamazepine.
DelavirdineThe metabolism of Delavirdine can be increased when combined with Carbamazepine.
deramciclaneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with deramciclane.
DesfluraneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desflurane.
DesipramineThe metabolism of Desipramine can be increased when combined with Carbamazepine.
DesipramineThe serum concentration of Carbamazepine can be increased when it is combined with Desipramine.
DesloratadineThe serum concentration of Carbamazepine can be increased when it is combined with Desloratadine.
DesloratadineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desloratadine.
DesmopressinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Desmopressin.
DesoximetasoneThe serum concentration of Desoximetasone can be decreased when it is combined with Carbamazepine.
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be decreased when it is combined with Carbamazepine.
DesvenlafaxineThe metabolism of Desvenlafaxine can be increased when combined with Carbamazepine.
DetomidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Detomidine.
DexamethasoneThe serum concentration of Carbamazepine can be decreased when it is combined with Dexamethasone.
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be decreased when it is combined with Carbamazepine.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dexbrompheniramine.
DexfenfluramineThe metabolism of Dexfenfluramine can be increased when combined with Carbamazepine.
DexmedetomidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dexmedetomidine.
DextromethorphanThe metabolism of Dextromethorphan can be increased when combined with Carbamazepine.
DextromethorphanThe serum concentration of Carbamazepine can be increased when it is combined with Dextromethorphan.
DextromoramideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dextromoramide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dextropropoxyphene.
DezocineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dezocine.
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Carbamazepine.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Carbamazepine.
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Carbamazepine.
DiclofenacThe serum concentration of Carbamazepine can be increased when it is combined with Diclofenac.
DiclofenamideThe serum concentration of Carbamazepine can be increased when it is combined with Diclofenamide.
DicoumarolThe serum concentration of Dicoumarol can be decreased when it is combined with Carbamazepine.
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Carbamazepine.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Carbamazepine.
DifenoxinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Difenoxin.
DiflorasoneThe serum concentration of Diflorasone can be decreased when it is combined with Carbamazepine.
DifluocortoloneThe serum concentration of Difluocortolone can be decreased when it is combined with Carbamazepine.
DifluprednateThe serum concentration of Difluprednate can be decreased when it is combined with Carbamazepine.
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Carbamazepine.
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Carbamazepine.
DihydrocodeineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dihydrocodeine.
DihydroergotamineThe metabolism of Dihydroergotamine can be increased when combined with Carbamazepine.
DihydroetorphineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dihydroetorphine.
DihydromorphineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dihydromorphine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be decreased when it is combined with Carbamazepine.
DiltiazemThe metabolism of Carbamazepine can be decreased when combined with Diltiazem.
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Carbamazepine.
DimenhydrinateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dimenhydrinate.
DinoprostoneThe metabolism of Dinoprostone can be increased when combined with Carbamazepine.
DiphenhydramineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Diphenhydramine.
DiphenoxylateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Diphenoxylate.
DipyridamoleThe serum concentration of Dipyridamole can be decreased when it is combined with Carbamazepine.
DipyridamoleThe serum concentration of Carbamazepine can be increased when it is combined with Dipyridamole.
DisopyramideThe metabolism of Disopyramide can be increased when combined with Carbamazepine.
DisulfiramThe metabolism of Disulfiram can be increased when combined with Carbamazepine.
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Carbamazepine.
DofetilideThe metabolism of Dofetilide can be increased when combined with Carbamazepine.
DolasetronThe metabolism of Dolasetron can be increased when combined with Carbamazepine.
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Carbamazepine.
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Carbamazepine.
DonepezilThe metabolism of Donepezil can be increased when combined with Carbamazepine.
DopamineThe metabolism of Dopamine can be increased when combined with Carbamazepine.
DoramectinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Doramectin.
DorzolamideThe serum concentration of Carbamazepine can be increased when it is combined with Dorzolamide.
DorzolamideThe metabolism of Dorzolamide can be increased when combined with Carbamazepine.
DosulepinThe metabolism of Dosulepin can be increased when combined with Carbamazepine.
DoxazosinThe serum concentration of Carbamazepine can be increased when it is combined with Doxazosin.
DoxazosinThe metabolism of Doxazosin can be increased when combined with Carbamazepine.
DoxepinThe metabolism of Doxepin can be increased when combined with Carbamazepine.
DoxepinThe serum concentration of Carbamazepine can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Carbamazepine.
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Carbamazepine.
DoxycyclineThe metabolism of Carbamazepine can be decreased when combined with Doxycycline.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
DoxylamineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when Carbamazepine is combined with DPDPE.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
DronabinolThe serum concentration of Dronabinol can be decreased when it is combined with Carbamazepine.
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Carbamazepine.
DronedaroneThe metabolism of Carbamazepine can be decreased when combined with Dronedarone.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Carbamazepine.
DrotebanolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Drotebanol.
DuloxetineThe metabolism of Duloxetine can be increased when combined with Carbamazepine.
DutasterideThe metabolism of Dutasteride can be increased when combined with Carbamazepine.
DyclonineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Dyclonine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Carbamazepine.
EcabetThe metabolism of Ecabet can be increased when combined with Carbamazepine.
EcgonineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ecgonine.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Carbamazepine is combined with ECGONINE METHYL ESTER.
EdoxabanThe serum concentration of Edoxaban can be decreased when it is combined with Carbamazepine.
EfavirenzThe serum concentration of Carbamazepine can be decreased when it is combined with Efavirenz.
EfavirenzThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Efavirenz.
ElafinThe metabolism of Elafin can be increased when combined with Carbamazepine.
ElbasvirThe serum concentration of Carbamazepine can be increased when it is combined with Elbasvir.
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Carbamazepine.
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Carbamazepine.
EltrombopagThe metabolism of Eltrombopag can be increased when combined with Carbamazepine.
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Carbamazepine.
EnalaprilThe metabolism of Enalapril can be increased when combined with Carbamazepine.
EnalaprilThe serum concentration of Carbamazepine can be increased when it is combined with Enalapril.
EnalaprilatThe metabolism of Enalaprilat can be increased when combined with Carbamazepine.
EnalkirenThe metabolism of Enalkiren can be increased when combined with Carbamazepine.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Carbamazepine.
EnfuvirtideThe metabolism of Enfuvirtide can be increased when combined with Carbamazepine.
EntacaponeThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Entacapone.
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Carbamazepine.
EnzalutamideThe serum concentration of Carbamazepine can be increased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Carbamazepine.
EplerenoneThe metabolism of Eplerenone can be increased when combined with Carbamazepine.
EpoprostenolThe metabolism of Epoprostenol can be increased when combined with Carbamazepine.
EquileninThe serum concentration of Equilenin can be decreased when it is combined with Carbamazepine.
EquilinThe serum concentration of Equilin can be decreased when it is combined with Carbamazepine.
ErgocalciferolThe metabolism of Ergocalciferol can be increased when combined with Carbamazepine.
Ergoloid mesylateThe metabolism of Ergoloid mesylate can be increased when combined with Carbamazepine.
ErgonovineThe metabolism of Ergonovine can be increased when combined with Carbamazepine.
ErgonovineThe serum concentration of Carbamazepine can be increased when it is combined with Ergonovine.
ErgotamineThe metabolism of Ergotamine can be increased when combined with Carbamazepine.
ErgotamineThe serum concentration of Carbamazepine can be increased when it is combined with Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Carbamazepine.
ErythromycinThe metabolism of Carbamazepine can be decreased when combined with Erythromycin.
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Carbamazepine.
EscitalopramThe metabolism of Carbamazepine can be decreased when combined with Escitalopram.
EscitalopramThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Escitalopram.
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Eslicarbazepine acetate.
Eslicarbazepine acetateThe serum concentration of Carbamazepine can be decreased when it is combined with Eslicarbazepine acetate.
EsmirtazapineThe metabolism of Esmirtazapine can be increased when combined with Carbamazepine.
EsomeprazoleThe metabolism of Esomeprazole can be increased when combined with Carbamazepine.
EstazolamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Estazolam.
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Carbamazepine.
Estradiol valerate/DienogestThe metabolism of Estradiol valerate/Dienogest can be increased when combined with Carbamazepine.
EstramustineThe metabolism of Estramustine can be increased when combined with Carbamazepine.
EstramustineThe serum concentration of Carbamazepine can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Estriol can be decreased when it is combined with Carbamazepine.
EstroneThe serum concentration of Estrone can be decreased when it is combined with Carbamazepine.
Estrone sulfateThe metabolism of Estrone sulfate can be increased when combined with Carbamazepine.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Carbamazepine.
EthanolCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Carbamazepine.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Carbamazepine.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Carbamazepine.
EthosuximideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethosuximide.
EthotoinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethotoin.
EthoxzolamideThe serum concentration of Carbamazepine can be increased when it is combined with Ethoxzolamide.
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Carbamazepine.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethyl carbamate.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethyl loflazepate.
EthylmorphineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethylmorphine.
EtidocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Etidocaine.
EtifoxineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Etifoxine.
EtizolamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Etizolam.
EtodolacThe metabolism of Etodolac can be increased when combined with Carbamazepine.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Carbamazepine.
EtonogestrelThe metabolism of Etonogestrel can be increased when combined with Carbamazepine.
EtoperidoneThe metabolism of Carbamazepine can be decreased when combined with Etoperidone.
EtoperidoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Etoperidone.
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Carbamazepine.
EtoposideThe serum concentration of Carbamazepine can be increased when it is combined with Etoposide.
EtoricoxibThe metabolism of Etoricoxib can be increased when combined with Carbamazepine.
EtorphineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Etorphine.
EtravirineThe serum concentration of Carbamazepine can be decreased when it is combined with Etravirine.
EtravirineThe metabolism of Etravirine can be increased when combined with Carbamazepine.
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Carbamazepine.
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Carbamazepine.
EzetimibeThe serum concentration of Ezetimibe can be decreased when it is combined with Carbamazepine.
EzogabineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ezogabine.
FamciclovirThe metabolism of Famciclovir can be increased when combined with Carbamazepine.
FamotidineThe metabolism of Famotidine can be increased when combined with Carbamazepine.
FelbamateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Felbamate.
FelodipineThe metabolism of Felodipine can be increased when combined with Carbamazepine.
FelodipineThe serum concentration of Carbamazepine can be increased when it is combined with Felodipine.
FencamfamineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fencamfamine.
FenfluramineThe metabolism of Carbamazepine can be decreased when combined with Fenfluramine.
FenfluramineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fenfluramine.
FenofibrateThe metabolism of Fenofibrate can be increased when combined with Carbamazepine.
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Carbamazepine.
FentanylThe serum concentration of Carbamazepine can be increased when it is combined with Fentanyl.
FesoterodineThe serum concentration of Fesoterodine can be decreased when it is combined with Carbamazepine.
FexofenadineThe serum concentration of Fexofenadine can be decreased when it is combined with Carbamazepine.
FexofenadineThe serum concentration of Carbamazepine can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Fidaxomicin can be decreased when it is combined with Carbamazepine.
FidaxomicinThe serum concentration of Carbamazepine can be increased when it is combined with Fidaxomicin.
FinasterideThe metabolism of Finasteride can be increased when combined with Carbamazepine.
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Carbamazepine.
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Carbamazepine.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Carbamazepine.
FluconazoleThe serum concentration of Carbamazepine can be increased when it is combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fludiazepam.
FludrocortisoneThe serum concentration of Fludrocortisone can be decreased when it is combined with Carbamazepine.
FlumethasoneThe serum concentration of Flumethasone can be decreased when it is combined with Carbamazepine.
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Carbamazepine.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Carbamazepine.
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Carbamazepine.
FlunitrazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Flunitrazepam.
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be decreased when it is combined with Carbamazepine.
FluocinonideThe serum concentration of Fluocinonide can be decreased when it is combined with Carbamazepine.
FluocortoloneThe serum concentration of Fluocortolone can be decreased when it is combined with Carbamazepine.
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Carbamazepine.
FluorouracilThe metabolism of Fluorouracil can be increased when combined with Carbamazepine.
FluoxetineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluoxetine.
FluoxetineThe serum concentration of Carbamazepine can be increased when it is combined with Fluoxetine.
FlupentixolThe serum concentration of Carbamazepine can be increased when it is combined with Flupentixol.
FlupentixolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Flupentixol.
FluphenazineThe serum concentration of Carbamazepine can be increased when it is combined with Fluphenazine.
FluphenazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluphenazine.
FluprednideneThe serum concentration of Fluprednidene can be decreased when it is combined with Carbamazepine.
FluprednisoloneThe serum concentration of Fluprednisolone can be decreased when it is combined with Carbamazepine.
FlurandrenolideThe serum concentration of Flurandrenolide can be decreased when it is combined with Carbamazepine.
FlurazepamThe serum concentration of Carbamazepine can be increased when it is combined with Flurazepam.
FlurazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Flurazepam.
FlurbiprofenThe metabolism of Flurbiprofen can be increased when combined with Carbamazepine.
FluspirileneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluspirilene.
FlutamideThe metabolism of Flutamide can be increased when combined with Carbamazepine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Carbamazepine.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluticasone Propionate.
FluvastatinThe metabolism of Fluvastatin can be increased when combined with Carbamazepine.
FluvoxamineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fluvoxamine.
FluvoxamineThe metabolism of Carbamazepine can be decreased when combined with Fluvoxamine.
FormoterolThe metabolism of Formoterol can be increased when combined with Carbamazepine.
FosamprenavirThe metabolism of Fosamprenavir can be increased when combined with Carbamazepine.
FosaprepitantThe serum concentration of Carbamazepine can be increased when it is combined with Fosaprepitant.
FosinoprilThe metabolism of Fosinopril can be increased when combined with Carbamazepine.
FosphenytoinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fosphenytoin.
FospropofolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Fospropofol.
FrovatriptanThe metabolism of Frovatriptan can be increased when combined with Carbamazepine.
FulvestrantThe metabolism of Fulvestrant can be increased when combined with Carbamazepine.
FurazolidoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Furazolidone.
Fusidic AcidThe serum concentration of Carbamazepine can be increased when it is combined with Fusidic Acid.
GabapentinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Gabapentin.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Carbamazepine is combined with gabapentin enacarbil.
GalantamineThe metabolism of Galantamine can be increased when combined with Carbamazepine.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Gamma Hydroxybutyric Acid.
GavestinelThe metabolism of Gavestinel can be increased when combined with Carbamazepine.
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Carbamazepine.
GefitinibThe serum concentration of Carbamazepine can be increased when it is combined with Gefitinib.
GeldanamycinThe metabolism of Geldanamycin can be increased when combined with Carbamazepine.
GemcitabineThe serum concentration of Gemcitabine can be decreased when it is combined with Carbamazepine.
GemfibrozilThe metabolism of Gemfibrozil can be increased when combined with Carbamazepine.
GenisteinThe serum concentration of Carbamazepine can be increased when it is combined with Genistein.
GenisteinThe metabolism of Genistein can be increased when combined with Carbamazepine.
GliclazideThe metabolism of Gliclazide can be increased when combined with Carbamazepine.
GlimepirideThe metabolism of Glimepiride can be increased when combined with Carbamazepine.
GlipizideThe metabolism of Glipizide can be increased when combined with Carbamazepine.
GlucosamineThe metabolism of Glucosamine can be increased when combined with Carbamazepine.
GlutethimideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Glutethimide.
GlyburideThe metabolism of Glyburide can be increased when combined with Carbamazepine.
GlyburideThe serum concentration of Carbamazepine can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Carbamazepine can be increased when it is combined with Glycerol.
GM6001The metabolism of GM6001 can be increased when combined with Carbamazepine.
Gramicidin DThe serum concentration of Carbamazepine can be increased when it is combined with Gramicidin D.
GranisetronThe metabolism of Granisetron can be increased when combined with Carbamazepine.
GrazoprevirThe serum concentration of Grazoprevir can be decreased when it is combined with Carbamazepine.
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Carbamazepine.
GrepafloxacinThe serum concentration of Carbamazepine can be increased when it is combined with Grepafloxacin.
GuanabenzThe metabolism of Guanabenz can be increased when combined with Carbamazepine.
GuanfacineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Guanfacine.
HalazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Halazepam.
HalofantrineThe metabolism of Halofantrine can be increased when combined with Carbamazepine.
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Carbamazepine.
HaloperidolThe serum concentration of Carbamazepine can be increased when it is combined with Haloperidol.
HalothaneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Halothane.
HeroinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Heroin.
HesperetinThe metabolism of Hesperetin can be increased when combined with Carbamazepine.
HexobarbitalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Hexobarbital.
HirulogThe metabolism of Hirulog can be increased when combined with Carbamazepine.
Histamine PhosphateThe metabolism of Histamine Phosphate can be increased when combined with Carbamazepine.
HydracarbazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Hydracarbazine.
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Carbamazepine.
HydrocodoneThe serum concentration of Hydrocodone can be decreased when it is combined with Carbamazepine.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Carbamazepine.
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Carbamazepine.
HydrocortisoneThe serum concentration of Carbamazepine can be increased when it is combined with Hydrocortisone.
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Carbamazepine.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Carbamazepine.
Hydroxyprogesterone caproateThe metabolism of Hydroxyprogesterone caproate can be increased when combined with Carbamazepine.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
HydroxyzineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Hydroxyzine.
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Carbamazepine.
IbuprofenThe serum concentration of Ibuprofen can be decreased when it is combined with Carbamazepine.
IdarubicinThe metabolism of Idarubicin can be increased when combined with Carbamazepine.
IdelalisibThe serum concentration of Carbamazepine can be increased when it is combined with Idelalisib.
IdelalisibThe serum concentration of Idelalisib can be decreased when it is combined with Carbamazepine.
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be increased when Ifosfamide is used in combination with Carbamazepine.
IloperidoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Iloperidone.
ImatinibThe metabolism of Carbamazepine can be decreased when combined with Imatinib.
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Carbamazepine.
ImipramineThe metabolism of Imipramine can be increased when combined with Carbamazepine.
ImipramineThe serum concentration of Carbamazepine can be increased when it is combined with Imipramine.
ImiquimodThe metabolism of Imiquimod can be increased when combined with Carbamazepine.
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Carbamazepine.
IndalpineThe metabolism of Carbamazepine can be decreased when combined with Indalpine.
IndalpineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Indalpine.
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Carbamazepine.
IndapamideThe metabolism of Indapamide can be increased when combined with Carbamazepine.
IndinavirThe serum concentration of Carbamazepine can be decreased when it is combined with Indinavir.
indisulamThe metabolism of indisulam can be increased when combined with Carbamazepine.
IndomethacinThe serum concentration of Indomethacin can be decreased when it is combined with Carbamazepine.
IndomethacinThe serum concentration of Carbamazepine can be increased when it is combined with Indomethacin.
Ipratropium bromideThe metabolism of Ipratropium bromide can be increased when combined with Carbamazepine.
IproclozideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Iproclozide.
IproniazidThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Iproniazid.
IrbesartanThe metabolism of Irbesartan can be increased when combined with Carbamazepine.
IrinotecanThe serum concentration of the active metabolites of Irinotecan can be reduced when Irinotecan is used in combination with Carbamazepine resulting in a loss in efficacy.
IsavuconazoniumThe serum concentration of the active metabolites of Isavuconazonium can be reduced when Isavuconazonium is used in combination with Carbamazepine resulting in a loss in efficacy.
IsavuconazoniumThe metabolism of Carbamazepine can be decreased when combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Isocarboxazid.
IsofluraneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Isoflurane.
IsoflurophateThe metabolism of Isoflurophate can be increased when combined with Carbamazepine.
IsoniazidThe metabolism of Carbamazepine can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe metabolism of Isosorbide Dinitrate can be increased when combined with Carbamazepine.
Isosorbide MononitrateThe metabolism of Isosorbide Mononitrate can be increased when combined with Carbamazepine.
IsradipineThe metabolism of Isradipine can be increased when combined with Carbamazepine.
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Carbamazepine.
ItraconazoleThe serum concentration of Carbamazepine can be increased when it is combined with Itraconazole.
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Carbamazepine.
IvacaftorThe serum concentration of Carbamazepine can be increased when it is combined with Ivacaftor.
IvacaftorThe serum concentration of Ivacaftor can be decreased when it is combined with Carbamazepine.
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Carbamazepine.
IvermectinThe serum concentration of Carbamazepine can be increased when it is combined with Ivermectin.
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Carbamazepine.
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Carbamazepine.
KetamineThe serum concentration of Carbamazepine can be increased when it is combined with Ketamine.
KetamineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ketamine.
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Carbamazepine.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Carbamazepine.
KetobemidoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ketobemidone.
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Carbamazepine.
KetoconazoleThe serum concentration of Carbamazepine can be increased when it is combined with Ketoconazole.
KetoprofenThe metabolism of Ketoprofen can be increased when combined with Carbamazepine.
LacosamideCarbamazepine may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamivudineThe serum concentration of Lamivudine can be decreased when it is combined with Carbamazepine.
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Carbamazepine.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Carbamazepine.
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Carbamazepine.
LansoprazoleThe serum concentration of Carbamazepine can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Carbamazepine.
LapatinibThe serum concentration of Carbamazepine can be increased when it is combined with Lapatinib.
LaquinimodThe metabolism of Laquinimod can be increased when combined with Carbamazepine.
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Carbamazepine.
LeflunomideThe metabolism of Leflunomide can be increased when combined with Carbamazepine.
LenalidomideThe serum concentration of Lenalidomide can be decreased when it is combined with Carbamazepine.
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Carbamazepine.
LepirudinThe metabolism of Lepirudin can be increased when combined with Carbamazepine.
LercanidipineThe metabolism of Lercanidipine can be increased when combined with Carbamazepine.
LesinuradThe metabolism of Lesinurad can be increased when combined with Carbamazepine.
LetrozoleThe metabolism of Letrozole can be increased when combined with Carbamazepine.
LevetiracetamThe serum concentration of Levetiracetam can be decreased when it is combined with Carbamazepine.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Carbamazepine.
LevobupivacaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levobupivacaine.
LevocabastineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levocabastine.
LevocetirizineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be decreased when it is combined with Carbamazepine.
LevofloxacinThe serum concentration of Carbamazepine can be increased when it is combined with Levofloxacin.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levomethadyl Acetate.
LevomilnacipranThe metabolism of Carbamazepine can be decreased when combined with Levomilnacipran.
LevomilnacipranThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levomilnacipran.
LevonorgestrelThe metabolism of Levonorgestrel can be increased when combined with Carbamazepine.
LevorphanolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Levorphanol.
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Carbamazepine.
LicofeloneThe metabolism of Licofelone can be increased when combined with Carbamazepine.
LidocaineThe serum concentration of Carbamazepine can be increased when it is combined with Lidocaine.
LidocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be decreased when it is combined with Carbamazepine.
LiothyronineThe serum concentration of Liothyronine can be decreased when it is combined with Carbamazepine.
LiotrixThe serum concentration of Liotrix can be decreased when it is combined with Carbamazepine.
LisinoprilThe metabolism of Lisinopril can be increased when combined with Carbamazepine.
LisinoprilThe serum concentration of Carbamazepine can be increased when it is combined with Lisinopril.
LisurideThe metabolism of Lisuride can be increased when combined with Carbamazepine.
LithiumThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Lithium.
LofentanilThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Lofentanil.
LomefloxacinThe metabolism of Lomefloxacin can be increased when combined with Carbamazepine.
LomitapideThe metabolism of Lomitapide can be increased when combined with Carbamazepine.
LomitapideThe serum concentration of Carbamazepine can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Carbamazepine.
LoperamideThe serum concentration of Carbamazepine can be increased when it is combined with Loperamide.
LopinavirThe metabolism of Lopinavir can be increased when combined with Carbamazepine.
LopinavirThe serum concentration of Carbamazepine can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Carbamazepine can be increased when it is combined with Loratadine.
LoratadineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Loratadine.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Carbamazepine.
LorcaserinThe metabolism of Lorcaserin can be increased when combined with Carbamazepine.
LornoxicamThe metabolism of Lornoxicam can be increased when combined with Carbamazepine.
LosartanThe serum concentration of Losartan can be decreased when it is combined with Carbamazepine.
LosartanThe serum concentration of Carbamazepine can be increased when it is combined with Losartan.
LovastatinThe metabolism of Lovastatin can be increased when combined with Carbamazepine.
LoxapineThe serum concentration of the active metabolites of Carbamazepine can be increased when Carbamazepine is used in combination with Loxapine.
LoxapineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Loxapine.
Lu AA21004The risk or severity of adverse effects can be increased when Carbamazepine is combined with Lu AA21004.
LuliconazoleThe serum concentration of Carbamazepine can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Carbamazepine can be decreased when it is combined with Lumacaftor.
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Carbamazepine.
LumiracoxibThe metabolism of Lumiracoxib can be increased when combined with Carbamazepine.
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Carbamazepine.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Carbamazepine.
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Carbamazepine.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Magnesium Sulfate.
MalathionThe metabolism of Malathion can be increased when combined with Carbamazepine.
MannitolThe serum concentration of Mannitol can be decreased when it is combined with Carbamazepine.
MaprotilineThe serum concentration of Carbamazepine can be increased when it is combined with Maprotiline.
MaprotilineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Maprotiline.
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Carbamazepine.
MebanazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mebanazine.
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Carbamazepine.
MebendazoleThe serum concentration of Carbamazepine can be increased when it is combined with Mebendazole.
MeclizineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Meclizine.
MedetomidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Medetomidine.
Medroxyprogesterone acetateThe metabolism of Medroxyprogesterone acetate can be increased when combined with Carbamazepine.
MedrysoneThe serum concentration of Medrysone can be decreased when it is combined with Carbamazepine.
Mefenamic acidThe metabolism of Mefenamic acid can be increased when combined with Carbamazepine.
MefloquineThe metabolism of Mefloquine can be increased when combined with Carbamazepine.
MefloquineThe serum concentration of Carbamazepine can be increased when it is combined with Mefloquine.
Megestrol acetateThe serum concentration of Carbamazepine can be increased when it is combined with Megestrol acetate.
MelatoninThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Melatonin.
MelengestrolThe serum concentration of Melengestrol can be decreased when it is combined with Carbamazepine.
MeloxicamThe metabolism of Meloxicam can be increased when combined with Carbamazepine.
MelperoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Melperone.
MenadioneThe metabolism of Menadione can be increased when combined with Carbamazepine.
MephenytoinThe metabolism of Mephenytoin can be increased when combined with Carbamazepine.
MepivacaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mepivacaine.
MeprobamateThe serum concentration of Carbamazepine can be increased when it is combined with Meprobamate.
MeprobamateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Meprobamate.
MesoridazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Mesoridazine.
MestranolThe metabolism of Mestranol can be increased when combined with Carbamazepine.
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Carbamazepine.
MetaxaloneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Metaxalone.
MethadoneThe serum concentration of Carbamazepine can be increased when it is combined with Methadone.
MethadoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methadone.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methadyl Acetate.
MethapyrileneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methapyrilene.
MethaqualoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methaqualone.
MethazolamideThe serum concentration of Carbamazepine can be increased when it is combined with Methazolamide.
MethocarbamolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methocarbamol.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Carbamazepine.
MethotrexateThe serum concentration of Methotrexate can be decreased when it is combined with Carbamazepine.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methotrimeprazine.
MethoxsalenThe metabolism of Methoxsalen can be increased when combined with Carbamazepine.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methoxyflurane.
MethsuximideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methsuximide.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Carbamazepine.
Methylene blueThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methylene blue.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methylphenobarbital.
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Carbamazepine.
MethyltestosteroneThe metabolism of Methyltestosterone can be increased when combined with Carbamazepine.
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Carbamazepine.
MetoprololThe serum concentration of Metoprolol can be decreased when it is combined with Carbamazepine.
MetoprololThe serum concentration of Carbamazepine can be increased when it is combined with Metoprolol.
MetronidazoleThe metabolism of Metronidazole can be increased when combined with Carbamazepine.
MetyrosineCarbamazepine may increase the sedative activities of Metyrosine.
MexiletineThe metabolism of Mexiletine can be increased when combined with Carbamazepine.
MianserinThe therapeutic efficacy of Carbamazepine can be decreased when used in combination with Mianserin.
MianserinThe metabolism of Mianserin can be increased when combined with Carbamazepine.
MibefradilThe metabolism of Mibefradil can be increased when combined with Carbamazepine.
MibefradilThe serum concentration of Carbamazepine can be increased when it is combined with Mibefradil.
MiconazoleThe metabolism of Miconazole can be increased when combined with Carbamazepine.
MiconazoleThe serum concentration of Carbamazepine can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Carbamazepine.
MifepristoneThe serum concentration of Mifepristone can be decreased when it is combined with Carbamazepine.
MifepristoneThe metabolism of Carbamazepine can be decreased when combined with Mifepristone.
MilnacipranThe metabolism of Carbamazepine can be decreased when combined with Milnacipran.
MilnacipranThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Milnacipran.
MinaprineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Minaprine.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Carbamazepine.
MirtazapineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Carbamazepine.
MitomycinThe serum concentration of Carbamazepine can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Carbamazepine can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be decreased when it is combined with Carbamazepine.
MoclobemideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Moclobemide.
ModafinilThe serum concentration of Carbamazepine can be decreased when it is combined with Modafinil.
ModafinilThe metabolism of Modafinil can be increased when combined with Carbamazepine.
MoexiprilThe metabolism of Moexipril can be increased when combined with Carbamazepine.
MolindoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Molindone.
MometasoneThe serum concentration of Mometasone can be decreased when it is combined with Carbamazepine.
MontelukastThe metabolism of Montelukast can be increased when combined with Carbamazepine.
MorphineThe serum concentration of Morphine can be decreased when it is combined with Carbamazepine.
MorphineThe serum concentration of Carbamazepine can be increased when it is combined with Morphine.
muraglitazarThe metabolism of muraglitazar can be increased when combined with Carbamazepine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Carbamazepine.
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe metabolism of N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline can be increased when combined with Carbamazepine.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
NabiloneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nabilone.
NabumetoneThe metabolism of Nabumetone can be increased when combined with Carbamazepine.
NadololThe serum concentration of Nadolol can be decreased when it is combined with Carbamazepine.
NafcillinThe serum concentration of Carbamazepine can be decreased when it is combined with Nafcillin.
NalbuphineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nalbuphine.
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Carbamazepine.
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Carbamazepine.
NaltrexoneThe serum concentration of Carbamazepine can be increased when it is combined with Naltrexone.
NaproxenThe metabolism of Naproxen can be increased when combined with Carbamazepine.
NaringeninThe serum concentration of Carbamazepine can be increased when it is combined with Naringenin.
NateglinideThe metabolism of Nateglinide can be increased when combined with Carbamazepine.
NCX 4016The metabolism of NCX 4016 can be increased when combined with Carbamazepine.
NefazodoneThe serum concentration of Carbamazepine can be increased when it is combined with Nefazodone.
NefazodoneThe metabolism of Nefazodone can be increased when combined with Carbamazepine.
NelfinavirThe serum concentration of Carbamazepine can be decreased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Carbamazepine can be increased when it is combined with Neostigmine.
NetupitantThe serum concentration of Carbamazepine can be increased when it is combined with Netupitant.
NetupitantThe serum concentration of Netupitant can be decreased when it is combined with Carbamazepine.
NevirapineThe metabolism of Nevirapine can be increased when combined with Carbamazepine.
NialamideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nialamide.
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Carbamazepine.
NicardipineThe serum concentration of Carbamazepine can be increased when it is combined with Nicardipine.
NiclosamideThe metabolism of Niclosamide can be increased when combined with Carbamazepine.
NicotineThe metabolism of Nicotine can be increased when combined with Carbamazepine.
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Carbamazepine.
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Carbamazepine.
NilotinibThe metabolism of Carbamazepine can be decreased when combined with Nilotinib.
NilutamideThe metabolism of Nilutamide can be increased when combined with Carbamazepine.
NilvadipineThe metabolism of Nilvadipine can be increased when combined with Carbamazepine.
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Carbamazepine.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Carbamazepine.
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Carbamazepine.
NisoldipineThe serum concentration of Carbamazepine can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Carbamazepine can be increased when it is combined with Nitrazepam.
NitrazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nitrazepam.
NitrendipineThe metabolism of Nitrendipine can be increased when combined with Carbamazepine.
NitrendipineThe serum concentration of Carbamazepine can be increased when it is combined with Nitrendipine.
Nitric OxideThe metabolism of Nitric Oxide can be increased when combined with Carbamazepine.
Nitrous oxideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Nitrous oxide.
NizatidineThe serum concentration of Nizatidine can be decreased when it is combined with Carbamazepine.
NorethisteroneThe metabolism of Norethisterone can be increased when combined with Carbamazepine.
NorethisteroneThe serum concentration of Carbamazepine can be decreased when it is combined with Norethisterone.
NorgestrelThe metabolism of Norgestrel can be increased when combined with Carbamazepine.
NormethadoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Normethadone.
NortriptylineThe metabolism of Nortriptyline can be increased when combined with Carbamazepine.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Carbamazepine.
OctamoxinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Octamoxin.
OlanzapineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Olanzapine.
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Carbamazepine.
OlaparibThe metabolism of Carbamazepine can be decreased when combined with Olaparib.
OlodaterolThe metabolism of Olodaterol can be increased when combined with Carbamazepine.
OlopatadineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Olopatadine.
OmapatrilatThe metabolism of Omapatrilat can be increased when combined with Carbamazepine.
OmbitasvirThe serum concentration of Ombitasvir can be decreased when it is combined with Carbamazepine.
OmeprazoleThe metabolism of Omeprazole can be increased when combined with Carbamazepine.
OmeprazoleThe serum concentration of Carbamazepine can be increased when it is combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ondansetron.
OpiumThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Opium.
OrlistatThe serum concentration of Carbamazepine can be decreased when it is combined with Orlistat.
OrphenadrineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Carbamazepine.
OsanetantThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Osanetant.
OsimertinibThe serum concentration of Carbamazepine can be increased when it is combined with Osimertinib.
OsimertinibThe serum concentration of Osimertinib can be decreased when it is combined with Carbamazepine.
OspemifeneThe metabolism of Ospemifene can be increased when combined with Carbamazepine.
OtamixabanThe metabolism of Otamixaban can be increased when combined with Carbamazepine.
OxaliplatinThe metabolism of Oxaliplatin can be increased when combined with Carbamazepine.
OxaprozinThe metabolism of Oxaprozin can be increased when combined with Carbamazepine.
OxazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxazepam.
OxcarbazepineThe serum concentration of the active metabolites of Oxcarbazepine can be reduced when Oxcarbazepine is used in combination with Carbamazepine resulting in a loss in efficacy.
OxiconazoleThe metabolism of Oxiconazole can be increased when combined with Carbamazepine.
OxprenololThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxprenolol.
OxtriphyllineThe metabolism of Oxtriphylline can be increased when combined with Carbamazepine.
OxybuprocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxybuprocaine.
OxybutyninThe metabolism of Oxybutynin can be increased when combined with Carbamazepine.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Carbamazepine.
OxymorphoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Oxymorphone.
P-NitrophenolThe serum concentration of Carbamazepine can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Carbamazepine.
PaclitaxelThe serum concentration of Carbamazepine can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Carbamazepine can be increased when it is combined with Palbociclib.
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Carbamazepine.
PaliperidoneThe serum concentration of Paliperidone can be decreased when it is combined with Carbamazepine.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Carbamazepine.
Palmitic AcidThe serum concentration of Carbamazepine can be increased when it is combined with Palmitic Acid.
PalonosetronThe metabolism of Palonosetron can be increased when combined with Carbamazepine.
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Carbamazepine.
PantoprazoleThe metabolism of Pantoprazole can be increased when combined with Carbamazepine.
PantoprazoleThe serum concentration of Carbamazepine can be increased when it is combined with Pantoprazole.
ParaldehydeCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Carbamazepine.
ParamethadioneThe metabolism of Paramethadione can be increased when combined with Carbamazepine.
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Carbamazepine.
ParecoxibThe metabolism of Parecoxib can be increased when combined with Carbamazepine.
PargylineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pargyline.
ParicalcitolThe metabolism of Paricalcitol can be increased when combined with Carbamazepine.
ParitaprevirThe metabolism of Paritaprevir can be increased when combined with Carbamazepine.
ParoxetineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Paroxetine.
ParoxetineThe serum concentration of Carbamazepine can be increased when it is combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Carbamazepine.
Peginterferon alfa-2bThe serum concentration of Carbamazepine can be increased when it is combined with Peginterferon alfa-2b.
PentamidineThe metabolism of Pentamidine can be increased when combined with Carbamazepine.
PentazocineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pentazocine.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Carbamazepine.
PentoxifyllineThe metabolism of Pentoxifylline can be increased when combined with Carbamazepine.
PerampanelThe serum concentration of Perampanel can be decreased when it is combined with Carbamazepine.
PerampanelThe risk or severity of adverse effects can be increased when Perampanel is combined with Carbamazepine.
PergolideThe metabolism of Pergolide can be increased when combined with Carbamazepine.
PerhexilineThe metabolism of Perhexiline can be increased when combined with Carbamazepine.
PerindoprilThe metabolism of Perindopril can be increased when combined with Carbamazepine.
PerindoprilThe serum concentration of Carbamazepine can be increased when it is combined with Perindopril.
PermethrinThe metabolism of Permethrin can be increased when combined with Carbamazepine.
PerospironeThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Perospirone.
PerphenazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Perphenazine.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Carbamazepine.
PhenacetinThe metabolism of Phenacetin can be increased when combined with Carbamazepine.
PhenelzineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Phenelzine.
PhenindioneThe serum concentration of Phenindione can be decreased when it is combined with Carbamazepine.
PheniprazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pheniprazine.
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Carbamazepine.
PhenoxybenzamineThe metabolism of Phenoxybenzamine can be increased when combined with Carbamazepine.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Phenoxyethanol.
PhenoxypropazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Phenoxypropazine.
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Carbamazepine.
PhenylbutazoneThe metabolism of Phenylbutazone can be increased when combined with Carbamazepine.
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Carbamazepine.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Carbamazepine.
PhosphoramidonThe metabolism of Phosphoramidon can be increased when combined with Carbamazepine.
PilocarpineThe metabolism of Pilocarpine can be increased when combined with Carbamazepine.
PimecrolimusThe metabolism of Pimecrolimus can be increased when combined with Carbamazepine.
PimozideThe serum concentration of Carbamazepine can be increased when it is combined with Pimozide.
PimozideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pimozide.
PinacidilThe metabolism of Pinacidil can be increased when combined with Carbamazepine.
PioglitazoneThe metabolism of Pioglitazone can be increased when combined with Carbamazepine.
PipamperoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pipamperone.
PipotiazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pipotiazine.
PirfenidoneThe serum concentration of Pirfenidone can be decreased when it is combined with Carbamazepine.
PirlindoleThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pirlindole.
PiroxicamThe metabolism of Piroxicam can be increased when combined with Carbamazepine.
PitavastatinThe serum concentration of Pitavastatin can be decreased when it is combined with Carbamazepine.
PivhydrazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pivhydrazine.
PizotifenThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pizotifen.
Platelet Activating FactorThe serum concentration of Carbamazepine can be decreased when it is combined with Platelet Activating Factor.
PodofiloxThe metabolism of Podofilox can be increased when combined with Carbamazepine.
PolythiazideThe risk or severity of adverse effects can be increased when Polythiazide is combined with Carbamazepine.
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Carbamazepine.
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with Carbamazepine.
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Carbamazepine.
PonatinibThe serum concentration of Carbamazepine can be increased when it is combined with Ponatinib.
PosaconazoleThe metabolism of Posaconazole can be increased when combined with Carbamazepine.
PosaconazoleThe serum concentration of Carbamazepine can be increased when it is combined with Posaconazole.
PramipexoleCarbamazepine may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Pramocaine.
PrasugrelThe metabolism of Prasugrel can be increased when combined with Carbamazepine.
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Carbamazepine.
PravastatinThe serum concentration of Carbamazepine can be increased when it is combined with Pravastatin.
PrazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Prazepam.
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Carbamazepine.
PrazosinThe serum concentration of Prazosin can be decreased when it is combined with Carbamazepine.
PrazosinThe serum concentration of Carbamazepine can be increased when it is combined with Prazosin.
PrednicarbateThe serum concentration of Prednicarbate can be decreased when it is combined with Carbamazepine.
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Carbamazepine.
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Carbamazepine.
PrednisoneThe serum concentration of Carbamazepine can be increased when it is combined with Prednisone.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Carbamazepine.
PregnenoloneThe serum concentration of Pregnenolone can be decreased when it is combined with Carbamazepine.
PrilocaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Prilocaine.
PrimaquineThe metabolism of Primaquine can be increased when combined with Carbamazepine.
PrimidoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Primidone.
PrinomastatThe metabolism of Prinomastat can be increased when combined with Carbamazepine.
ProbenecidThe serum concentration of Carbamazepine can be increased when it is combined with Probenecid.
ProcaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Procaine.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Carbamazepine.
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Carbamazepine.
ProguanilThe metabolism of Proguanil can be increased when combined with Carbamazepine.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Carbamazepine.
PromethazineThe serum concentration of Carbamazepine can be increased when it is combined with Promethazine.
PromethazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Promethazine.
PropacetamolThe metabolism of Propacetamol can be increased when combined with Carbamazepine.
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Carbamazepine.
PropafenoneThe serum concentration of Carbamazepine can be increased when it is combined with Propafenone.
ProparacaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Proparacaine.
PropofolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Propofol.
PropoxycaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Propoxycaine.
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Carbamazepine.
PropranololThe serum concentration of Carbamazepine can be increased when it is combined with Propranolol.
ProtriptylineThe metabolism of Protriptyline can be increased when combined with Carbamazepine.
ProtriptylineThe serum concentration of Carbamazepine can be increased when it is combined with Protriptyline.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Carbamazepine.
PSD502The risk or severity of adverse effects can be increased when Carbamazepine is combined with PSD502.
PyrazinamideThe metabolism of Pyrazinamide can be increased when combined with Carbamazepine.
QuazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Quazepam.
QuercetinThe serum concentration of Carbamazepine can be increased when it is combined with Quercetin.
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Carbamazepine.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Carbamazepine.
QuinacrineThe metabolism of Quinacrine can be increased when combined with Carbamazepine.
QuinacrineThe serum concentration of Carbamazepine can be increased when it is combined with Quinacrine.
QuinaprilThe metabolism of Quinapril can be increased when combined with Carbamazepine.
QuinethazoneThe risk or severity of adverse effects can be increased when Quinethazone is combined with Carbamazepine.
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Carbamazepine.
QuinidineThe serum concentration of Carbamazepine can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Quinine can be decreased when it is combined with Carbamazepine.
QuinineThe serum concentration of Carbamazepine can be increased when it is combined with Quinine.
RabeprazoleThe metabolism of Rabeprazole can be increased when combined with Carbamazepine.
RaloxifeneThe metabolism of Raloxifene can be increased when combined with Carbamazepine.
RamelteonThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ramelteon.
RamiprilThe metabolism of Ramipril can be increased when combined with Carbamazepine.
RanitidineThe serum concentration of Ranitidine can be decreased when it is combined with Carbamazepine.
RanitidineThe serum concentration of Carbamazepine can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Carbamazepine can be increased when it is combined with Ranolazine.
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Carbamazepine.
RasagilineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Rasagiline.
ReboxetineThe metabolism of Reboxetine can be increased when combined with Carbamazepine.
ReboxetineThe serum concentration of Carbamazepine can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Carbamazepine.
RegorafenibThe serum concentration of Carbamazepine can be increased when it is combined with Regorafenib.
RemifentanilThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Remifentanil.
RemikirenThe metabolism of Remikiren can be increased when combined with Carbamazepine.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Carbamazepine.
RepaglinideThe metabolism of Repaglinide can be increased when combined with Carbamazepine.
ReserpineThe serum concentration of Carbamazepine can be decreased when it is combined with Reserpine.
ResveratrolThe metabolism of Resveratrol can be increased when combined with Carbamazepine.
RetapamulinThe metabolism of Retapamulin can be increased when combined with Carbamazepine.
RifabutinThe metabolism of Rifabutin can be increased when combined with Carbamazepine.
RifampicinThe serum concentration of Carbamazepine can be decreased when it is combined with Rifampicin.
RifapentineThe metabolism of Carbamazepine can be increased when combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Carbamazepine.
RilpivirineThe metabolism of Rilpivirine can be increased when combined with Carbamazepine.
RilpivirineThe serum concentration of Carbamazepine can be increased when it is combined with Rilpivirine.
RiluzoleThe metabolism of Riluzole can be increased when combined with Carbamazepine.
RimexoloneThe serum concentration of Rimexolone can be decreased when it is combined with Carbamazepine.
RimonabantThe metabolism of Rimonabant can be increased when combined with Carbamazepine.
RiociguatThe metabolism of Riociguat can be increased when combined with Carbamazepine.
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Carbamazepine.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Carbamazepine.
RitonavirThe serum concentration of Ritonavir can be decreased when it is combined with Carbamazepine.
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Carbamazepine.
RizatriptanThe metabolism of Rizatriptan can be increased when combined with Carbamazepine.
RofecoxibThe metabolism of Rofecoxib can be increased when combined with Carbamazepine.
RoflumilastThe serum concentration of Roflumilast can be decreased when it is combined with Carbamazepine.
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Carbamazepine.
RolapitantThe serum concentration of Carbamazepine can be increased when it is combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Carbamazepine.
RomifidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Romifidine.
RopiniroleCarbamazepine may increase the sedative activities of Ropinirole.
RopiniroleThe metabolism of Carbamazepine can be decreased when combined with Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Carbamazepine.
RosiglitazoneThe metabolism of Rosiglitazone can be increased when combined with Carbamazepine.
RosuvastatinThe metabolism of Rosuvastatin can be increased when combined with Carbamazepine.
RotigotineCarbamazepine may increase the sedative activities of Rotigotine.
RoxithromycinThe metabolism of Roxithromycin can be increased when combined with Carbamazepine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Carbamazepine.
RuxolitinibThe metabolism of Ruxolitinib can be increased when combined with Carbamazepine.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Carbamazepine is combined with S-Ethylisothiourea.
SafrazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Safrazine.
Salicylic acidThe serum concentration of Salicylic acid can be decreased when it is combined with Carbamazepine.
SalmeterolThe metabolism of Salmeterol can be increased when combined with Carbamazepine.
SaquinavirThe serum concentration of Carbamazepine can be decreased when it is combined with Saquinavir.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Carbamazepine.
ScopolamineThe serum concentration of Carbamazepine can be increased when it is combined with Scopolamine.
ScopolamineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Scopolamine.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Carbamazepine.
SelegilineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Selegiline.
SelegilineThe serum concentration of Carbamazepine can be increased when it is combined with Selegiline.
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Carbamazepine.
SeratrodastThe metabolism of Seratrodast can be increased when combined with Carbamazepine.
SertindoleThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Sertindole.
SertralineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Sertraline.
SertralineThe serum concentration of Carbamazepine can be increased when it is combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Sevoflurane.
SibutramineThe metabolism of Sibutramine can be increased when combined with Carbamazepine.
SildenafilThe metabolism of Sildenafil can be increased when combined with Carbamazepine.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Carbamazepine.
SiltuximabThe serum concentration of Carbamazepine can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Carbamazepine can be increased when it is combined with Simeprevir.
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Carbamazepine.
SimvastatinThe metabolism of Simvastatin can be increased when combined with Carbamazepine.
SimvastatinThe serum concentration of Carbamazepine can be increased when it is combined with Simvastatin.
SirolimusThe metabolism of Sirolimus can be increased when combined with Carbamazepine.
SirolimusThe serum concentration of Carbamazepine can be decreased when it is combined with Sirolimus.
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Carbamazepine.
SitaxentanThe metabolism of Sitaxentan can be increased when combined with Carbamazepine.
Sodium oxybateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Sodium oxybate.
SofosbuvirThe serum concentration of Sofosbuvir can be decreased when it is combined with Carbamazepine.
SolifenacinThe metabolism of Solifenacin can be increased when combined with Carbamazepine.
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Carbamazepine.
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Carbamazepine.
SorafenibThe serum concentration of Carbamazepine can be increased when it is combined with Sorafenib.
SparfloxacinThe serum concentration of Sparfloxacin can be decreased when it is combined with Carbamazepine.
SphingosineThe serum concentration of Sphingosine can be decreased when it is combined with Carbamazepine.
SpiramycinThe metabolism of Spiramycin can be increased when combined with Carbamazepine.
SpiraprilThe metabolism of Spirapril can be increased when combined with Carbamazepine.
SpironolactoneThe serum concentration of Carbamazepine can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Carbamazepine can be decreased when it is combined with St. John's Wort.
StaurosporineThe serum concentration of Carbamazepine can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Carbamazepine can be increased when it is combined with Stiripentol.
StiripentolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Stiripentol.
StreptozocinThe serum concentration of Carbamazepine can be decreased when it is combined with Streptozocin.
SufentanilThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Sufentanil.
SulfadiazineThe metabolism of Sulfadiazine can be increased when combined with Carbamazepine.
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be increased when combined with Carbamazepine.
SulfamoxoleThe metabolism of Sulfamoxole can be increased when combined with Carbamazepine.
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be increased when combined with Carbamazepine.
SulfinpyrazoneThe serum concentration of Carbamazepine can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Carbamazepine can be decreased when combined with Sulfisoxazole.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Carbamazepine.
SumatriptanThe serum concentration of Carbamazepine can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Carbamazepine.
SunitinibThe serum concentration of Carbamazepine can be increased when it is combined with Sunitinib.
SuprofenThe metabolism of Suprofen can be increased when combined with Carbamazepine.
SuvorexantThe serum concentration of Suvorexant can be decreased when it is combined with Carbamazepine.
SuvorexantThe risk or severity of adverse effects can be increased when Suvorexant is combined with Carbamazepine.
Synthetic Conjugated Estrogens, AThe metabolism of Synthetic Conjugated Estrogens, A can be increased when combined with Carbamazepine.
Synthetic Conjugated Estrogens, BThe metabolism of Synthetic Conjugated Estrogens, B can be increased when combined with Carbamazepine.
TacrineThe serum concentration of Carbamazepine can be increased when it is combined with Tacrine.
TacrineThe metabolism of Tacrine can be increased when combined with Carbamazepine.
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Carbamazepine.
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Carbamazepine.
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Carbamazepine.
TamsulosinThe metabolism of Tamsulosin can be increased when combined with Carbamazepine.
TapentadolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tapentadol.
TasimelteonThe serum concentration of Tasimelteon can be decreased when it is combined with Carbamazepine.
TasimelteonThe risk or severity of adverse effects can be increased when Tasimelteon is combined with Carbamazepine.
TasosartanThe metabolism of Tasosartan can be increased when combined with Carbamazepine.
Taurochenodeoxycholic acidThe metabolism of Taurochenodeoxycholic acid can be increased when combined with Carbamazepine.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be decreased when it is combined with Carbamazepine.
Taurocholic AcidThe serum concentration of Carbamazepine can be increased when it is combined with Taurocholic Acid.
TazaroteneThe metabolism of Tazarotene can be increased when combined with Carbamazepine.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Carbamazepine.
TelaprevirThe serum concentration of Carbamazepine can be increased when it is combined with Telaprevir.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Carbamazepine.
TelithromycinThe metabolism of Telithromycin can be increased when combined with Carbamazepine.
TelmisartanThe serum concentration of Carbamazepine can be increased when it is combined with Telmisartan.
TemafloxacinThe metabolism of Temafloxacin can be increased when combined with Carbamazepine.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Carbamazepine.
TemocaprilThe metabolism of Temocapril can be increased when combined with Carbamazepine.
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Carbamazepine.
TemsirolimusThe serum concentration of Carbamazepine can be increased when it is combined with Temsirolimus.
TeniposideThe metabolism of Teniposide can be increased when combined with Carbamazepine.
TenofovirThe metabolism of Carbamazepine can be decreased when combined with Tenofovir.
TenoxicamThe metabolism of Tenoxicam can be increased when combined with Carbamazepine.
TerazosinThe serum concentration of Carbamazepine can be increased when it is combined with Terazosin.
TerbinafineThe metabolism of Terbinafine can be increased when combined with Carbamazepine.
TerfenadineThe metabolism of Terfenadine can be increased when combined with Carbamazepine.
TerfenadineThe serum concentration of Carbamazepine can be increased when it is combined with Terfenadine.
TeriflunomideThe serum concentration of Carbamazepine can be decreased when it is combined with Teriflunomide.
TesmilifeneThe metabolism of Tesmilifene can be increased when combined with Carbamazepine.
TesmilifeneThe serum concentration of Carbamazepine can be decreased when it is combined with Tesmilifene.
TestosteroneThe metabolism of Testosterone can be increased when combined with Carbamazepine.
TestosteroneThe serum concentration of Carbamazepine can be increased when it is combined with Testosterone.
TetrabenazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tetrabenazine.
TetracaineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tetracaine.
TetracyclineThe metabolism of Tetracycline can be increased when combined with Carbamazepine.
TetrodotoxinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tetrodotoxin.
ThalidomideCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Carbamazepine.
TheobromineThe metabolism of Theobromine can be increased when combined with Carbamazepine.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Carbamazepine.
TheophyllineThe metabolism of Carbamazepine can be decreased when combined with Theophylline.
ThiabendazoleThe metabolism of Thiabendazole can be increased when combined with Carbamazepine.
ThiamylalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Thiamylal.
ThiopentalThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Thiopental.
ThioridazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Thioridazine.
ThiorphanThe metabolism of Thiorphan can be increased when combined with Carbamazepine.
ThiotepaThe metabolism of Thiotepa can be increased when combined with Carbamazepine.
ThiothixeneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Thiothixene.
Thyroid, porcineThe serum concentration of Thyroid, porcine can be decreased when it is combined with Carbamazepine.
TiagabineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tiagabine.
TianeptineThe metabolism of Tianeptine can be increased when combined with Carbamazepine.
TicagrelorThe serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Carbamazepine resulting in a loss in efficacy.
TicagrelorThe serum concentration of Carbamazepine can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Ticlopidine can be increased when combined with Carbamazepine.
TiletamineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tiletamine.
TimololThe serum concentration of Timolol can be decreased when it is combined with Carbamazepine.
TinidazoleThe metabolism of Tinidazole can be increased when combined with Carbamazepine.
TiotropiumThe metabolism of Tiotropium can be increased when combined with Carbamazepine.
TipranavirThe metabolism of Tipranavir can be increased when combined with Carbamazepine.
TixocortolThe serum concentration of Tixocortol can be decreased when it is combined with Carbamazepine.
TizanidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tizanidine.
TocilizumabThe serum concentration of Carbamazepine can be decreased when it is combined with Tocilizumab.
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Carbamazepine.
TolbutamideThe metabolism of Tolbutamide can be increased when combined with Carbamazepine.
TolcaponeThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tolcapone.
ToloxatoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Toloxatone.
TolterodineThe metabolism of Tolterodine can be increased when combined with Carbamazepine.
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Carbamazepine.
TolvaptanThe serum concentration of Carbamazepine can be increased when it is combined with Tolvaptan.
TopiramateThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Carbamazepine.
TorasemideThe metabolism of Torasemide can be increased when combined with Carbamazepine.
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Carbamazepine.
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Carbamazepine.
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
TramadolThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tramadol.
TrandolaprilThe metabolism of Trandolapril can be increased when combined with Carbamazepine.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Trans-2-Phenylcyclopropylamine.
TranylcypromineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Carbamazepine.
TrazodoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Trazodone.
TrazodoneThe serum concentration of Carbamazepine can be decreased when it is combined with Trazodone.
TreprostinilThe serum concentration of Treprostinil can be decreased when it is combined with Carbamazepine.
TretinoinThe metabolism of Tretinoin can be increased when combined with Carbamazepine.
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Carbamazepine.
TriamtereneThe metabolism of Triamterene can be increased when combined with Carbamazepine.
TriazolamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Triazolam.
TrichlormethiazideThe risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Carbamazepine.
TrifluoperazineThe serum concentration of Carbamazepine can be increased when it is combined with Trifluoperazine.
TrifluoperazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Carbamazepine can be increased when it is combined with Triflupromazine.
TriflupromazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Triflupromazine.
TrimethadioneThe metabolism of Trimethadione can be increased when combined with Carbamazepine.
TrimethoprimThe metabolism of Trimethoprim can be increased when combined with Carbamazepine.
TrimethoprimThe serum concentration of Carbamazepine can be decreased when it is combined with Trimethoprim.
TrimipramineThe metabolism of Trimipramine can be increased when combined with Carbamazepine.
TrimipramineThe serum concentration of Carbamazepine can be increased when it is combined with Trimipramine.
TriprolidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Triprolidine.
TroglitazoneThe metabolism of Troglitazone can be increased when combined with Carbamazepine.
TroleandomycinThe metabolism of Troleandomycin can be increased when combined with Carbamazepine.
TroleandomycinThe serum concentration of Carbamazepine can be increased when it is combined with Troleandomycin.
UbenimexThe metabolism of Ubenimex can be increased when combined with Carbamazepine.
UdenafilThe metabolism of Udenafil can be increased when combined with Carbamazepine.
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Carbamazepine.
UmeclidiniumThe serum concentration of Umeclidinium can be decreased when it is combined with Carbamazepine.
ValdecoxibThe metabolism of Valdecoxib can be increased when combined with Carbamazepine.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Carbamazepine.
ValsartanThe metabolism of Valsartan can be increased when combined with Carbamazepine.
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Carbamazepine.
VanoxerineThe metabolism of Vanoxerine can be increased when combined with Carbamazepine.
VardenafilThe metabolism of Vardenafil can be increased when combined with Carbamazepine.
VecuroniumThe serum concentration of Vecuronium can be decreased when it is combined with Carbamazepine.
VemurafenibThe serum concentration of Carbamazepine can be increased when it is combined with Vemurafenib.
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Carbamazepine.
VenlafaxineThe metabolism of Carbamazepine can be decreased when combined with Venlafaxine.
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Carbamazepine.
VerapamilThe metabolism of Carbamazepine can be decreased when combined with Verapamil.
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Carbamazepine.
VicrivirocThe metabolism of Vicriviroc can be increased when combined with Carbamazepine.
VigabatrinThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Vigabatrin.
VilanterolThe metabolism of Vilanterol can be increased when combined with Carbamazepine.
VilazodoneThe metabolism of Carbamazepine can be decreased when combined with Vilazodone.
VilazodoneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Vilazodone.
VildagliptinThe metabolism of Vildagliptin can be increased when combined with Carbamazepine.
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Carbamazepine.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Carbamazepine.
VincristineThe serum concentration of Carbamazepine can be decreased when it is combined with Vincristine.
VindesineThe metabolism of Vindesine can be increased when combined with Carbamazepine.
VinorelbineThe metabolism of Vinorelbine can be increased when combined with Carbamazepine.
VinorelbineThe serum concentration of Carbamazepine can be increased when it is combined with Vinorelbine.
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Carbamazepine.
VorapaxarThe serum concentration of Vorapaxar can be decreased when it is combined with Carbamazepine.
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Carbamazepine.
VoriconazoleThe metabolism of Carbamazepine can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Vortioxetine.
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Carbamazepine.
XimelagatranThe metabolism of Ximelagatran can be increased when combined with Carbamazepine.
XylazineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Xylazine.
YohimbineThe metabolism of Yohimbine can be increased when combined with Carbamazepine.
ZafirlukastThe metabolism of Zafirlukast can be increased when combined with Carbamazepine.
ZalcitabineThe metabolism of Zalcitabine can be increased when combined with Carbamazepine.
ZaleplonThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Zaleplon.
ZaltoprofenThe metabolism of Zaltoprofen can be increased when combined with Carbamazepine.
ZiconotideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Carbamazepine.
ZileutonThe metabolism of Zileuton can be increased when combined with Carbamazepine.
ZimelidineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Zimelidine.
ZimelidineThe serum concentration of Carbamazepine can be increased when it is combined with Zimelidine.
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Carbamazepine.
ZiprasidoneThe metabolism of Carbamazepine can be decreased when combined with Ziprasidone.
ZolazepamThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Zolazepam.
ZolmitriptanThe metabolism of Zolmitriptan can be increased when combined with Carbamazepine.
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.
ZolpidemThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Zolpidem.
ZomepiracThe metabolism of Zomepirac can be increased when combined with Carbamazepine.
ZonisamideThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Zonisamide.
ZopicloneThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Zopiclone.
ZotepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Zotepine.
ZuclopenthixolThe serum concentration of Zuclopenthixol can be decreased when it is combined with Carbamazepine.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Carbamazepine.
Food Interactions
  • Avoid alcohol.
  • Avoid taking grapefruit or grapefruit juice throughout treatment.
  • Grapefruit can significantly increase serum levels of this product.
  • Take with food, increases availability and reduces irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Yang YC, Huang CS, Kuo CC: Lidocaine, carbamazepine, and imipramine have partially overlapping binding sites and additive inhibitory effect on neuronal Na+ channels. Anesthesiology. 2010 Jul;113(1):160-74. doi: 10.1097/ALN.0b013e3181dc1dd6. [PubMed:20526191 ]
  4. Yang YC, Kuo CC: Inhibition of Na(+) current by imipramine and related compounds: different binding kinetics as an inactivation stabilizer and as an open channel blocker. Mol Pharmacol. 2002 Nov;62(5):1228-37. [PubMed:12391287 ]
  5. Lipkind GM, Fozzard HA: Molecular model of anticonvulsant drug binding to the voltage-gated sodium channel inner pore. Mol Pharmacol. 2010 Oct;78(4):631-8. doi: 10.1124/mol.110.064683. Epub 2010 Jul 19. [PubMed:20643904 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8. [PubMed:18537577 ]
  2. Levy RH: Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia. 1995;36 Suppl 5:S8-13. [PubMed:8806399 ]
  3. Cazali N, Tran A, Treluyer JM, Rey E, d'Athis P, Vincent J, Pons G: Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003 Nov;56(5):526-36. [PubMed:14651727 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Cazali N, Tran A, Treluyer JM, Rey E, d'Athis P, Vincent J, Pons G: Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003 Nov;56(5):526-36. [PubMed:14651727 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Wang B, Zhou SF: Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. Curr Med Chem. 2009;16(31):4066-218. [PubMed:19754423 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Molecular Weight:
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A7
Uniprot ID:
P24462
Molecular Weight:
57525.03 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Glucuronosyltransferase activity
Specific Function:
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol suggests it may play an important role in regulating the level and activity of these potent and active estrogen metabolites. Is also active with androsterone, hyodeoxycholic acid and tetrachlorocatechol...
Gene Name:
UGT2B7
Uniprot ID:
P16662
Molecular Weight:
60694.12 Da
References
  1. Kim KA, Oh SO, Park PW, Park JY: Effect of probenecid on the pharmacokinetics of carbamazepine in healthy subjects. Eur J Clin Pharmacol. 2005 Jun;61(4):275-80. Epub 2005 May 25. [PubMed:15915352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Geick A, Eichelbaum M, Burk O: Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001 May 4;276(18):14581-7. Epub 2001 Jan 31. [PubMed:11297522 ]
  2. Owen A, Pirmohamed M, Tettey JN, Morgan P, Chadwick D, Park BK: Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol. 2001 Apr;51(4):345-9. [PubMed:11318771 ]
  3. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW: Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. [PubMed:12438524 ]
  4. Baltes S, Gastens AM, Fedrowitz M, Potschka H, Kaever V, Loscher W: Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology. 2007 Feb;52(2):333-46. Epub 2006 Oct 10. [PubMed:17045309 ]
  5. Faassen F, Vogel G, Spanings H, Vromans H: Caco-2 permeability, P-glycoprotein transport ratios and brain penetration of heterocyclic drugs. Int J Pharm. 2003 Sep 16;263(1-2):113-22. [PubMed:12954186 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Transmembrane transporter activity
Specific Function:
Can activate specifically hydrolysis of GTP bound to RAC1 and CDC42, but not RALA. Mediates ATP-dependent transport of S-(2,4-dinitrophenyl)-glutathione (DNP-SG) and doxorubicin (DOX) and is the major ATP-dependent transporter of glutathione conjugates of electrophiles (GS-E) and DOX in erythrocytes. Can catalyze transport of glutathione conjugates and xenobiotics, and may contribute to the mul...
Gene Name:
RALBP1
Uniprot ID:
Q15311
Molecular Weight:
76062.86 Da
References
  1. Awasthi S, Hallene KL, Fazio V, Singhal SS, Cucullo L, Awasthi YC, Dini G, Janigro D: RLIP76, a non-ABC transporter, and drug resistance in epilepsy. BMC Neurosci. 2005 Sep 27;6:61. [PubMed:16188027 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Organic anion transmembrane transporter activity
Specific Function:
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name:
ABCC2
Uniprot ID:
Q92887
Molecular Weight:
174205.64 Da
References
  1. Ufer M, Mosyagin I, Muhle H, Jacobsen T, Haenisch S, Hasler R, Faltraco F, Remmler C, von Spiczak S, Kroemer HK, Runge U, Boor R, Stephani U, Cascorbi I: Non-response to antiepileptic pharmacotherapy is associated with the ABCC2 -24C>T polymorphism in young and adult patients with epilepsy. Pharmacogenet Genomics. 2009 May;19(5):353-62. [PubMed:19415824 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 26, 2016 02:13